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Abstract
Venous thromboembolism (VTE) are the greatest single cause of maternal 
mortality in pregnant women in developed countries. Pregnancy is a 
hypercoagulable state and brings about an enhanced risk of deep venous 
thrombosis (DVT) in otherwise healthy women. Traditionally, unfractionated 
heparin (UFH) has been used for treatment of DVT during pregnancy. 
We showed in our observational study that low molecular weight heparin 
(LMWH) is as eff ective and safe as UFH in the treatment of DVT during 
pregnancy. Although DVT during pregnancy is oft en massive, increasing 
the risk of developing long-term consequences, namely post-thrombotic 
syndrome (PTS), only 11% of all patients had confi rmed PTS 3–4 years 
aft er DVT. In our studies the prevalence of PTS was not dependent on 
treatment (UFH vs. LMWH). Low molecular weight heparin is more easily 
administered, few laboratory controls are required and the hospital stay is 
shorter, factors that lower the costs of treatment.
Cervical insuffi  ciency is defi ned as repeated very preterm delivery during 
the second or early third trimester. Infection is a well-known risk factor of 
preterm delivery. We found overpresentation of thrombophilic mutations 
(FV Leiden, prothrombin) among 42 patients with cervical insuffi  ciency 
compared with controls (OR 6.7, 95% CI 2.7–18.4). Th us, thrombophilia 
might be a risk factor of cervical insuffi  ciency possibly explained by 
interaction of coagulation and infl ammation processes.
Th e presence of antiphospholipid (aPL) antibodies increases the risk 
for recurrent miscarriage (RM). Annexins are proteins which all bind to 
anionic phospholipids (PLs) preventing clotting on vascular phospholipid 
surfaces. In this study plasma concentrations of circulating annexin IV and 
V were investigated in 77 pregnancies at the beginning of pregnancy among 
women with a history of RM, and in connection to their aPL antibody 
status. Control group consisted unselected pregnant patients (n=25) without 
history of adverse pregnancy outcome. Plasma levels of annexin V were 
signifi cantly higher at the beginning (≤5th week) of pregnancy in women 
with aPL antibodies (lupus anticoagulant, aCL, antiphosphatidylserine, 
antiprothrombin, and/or anti-β2GPI) compared with those without aPL 
antibodies (P=0.03). Levels of circulating annexin V were also higher at 
the 6th (P= 0.01) and 8th week of pregnancy in subjects with aPL antibodies 
(P=0.01). Results support the hypothesis that aPL could displace annexin 
from anionic phospholipid surfaces of syncytiotrophoblasts (STBs) and may 
exert procoagulant activities on the surfaces of STBs
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Recurrent miscarriage (RM) has been suggested to be caused by 
mutations in genes coding for various coagulation factors resulting in 
thrombophilia. In the last study of my thesis were investigated the prevalence 
of thrombomodulin (TM) and endothelial protein C receptor polymorphism 
EPCR among 40 couples and six women suff ering RM. Th is study showed 




Venous thromboembolism(VTE) is the greatest single cause of maternal 
mortality in pregnant women in developed countries (Greer 1999). Normal 
pregnancy is associated with several changes in all levels of hemostasis, 
as increased concentration of procoagulants, decreased levels of natural 
anticoagulants and diminished fi brinolytic activity render pregnancy a 
highly hypercoagulable state (Bremme 2003). Venous thromboembolism is 
rare in healthy pregnant women as natural anticoagulants slow up exessive 
fi brin formation and fi nally the fi brinolytic system gets rid of the formed 
fi brin. However, thrombophilias, either acquired or hereditary, may shift  
the hemostatic balance towards enhanced coagulation (Greer 2003). 
Th rombophilias can be found in as many as 50% of patients with VTE 
during pregnancy (Greer 1999).
Acquired and hereditary thrombophilias have been associated with 
increased risks of pregnancy complications such as recurrent miscarriage, 
late fetal loss, preeclampsia, intrauterine growth restriction and placental 
abruption (Robertson et al 2006). One of the major acquired thrombophilias 
is related to antiphospholipid (aPL) antibodies. An association between 
these antibodies and pregnancy complications was described as early as in 
the 1980s (Harris et al 1987, Branch et al 1989), but the pathophysiology is 
still unclear. Antiphospholipid antibodies are known to promote coagulation 
activation via many mechanisms and they lead to thrombotic events in the 
placenta. Th e latest pathophysiological concept is related to annexins, natural 
local anticoagulants. Targeting of the annexin V anticoagulant shield may 
be a signifi cant mechanism for thrombosis and pregnancy losses related to 
antiphospholipid antibodies (Rand et al 1994, Rand et al 1997).
Growing evidence from case-control studies and recent meta-analyses 
(Rey et al 2003, Kujovich 2004) has shown an association between hereditary 
thrombophilia and recurrent miscarriage. Beside the well known hereditary 
thrombophilias related to coagulation pathways (F V Leiden, Prothrombin), 
studies in mice highlight also an important role for the thrombomodulin 
(TM) and endothelial protein C receptor (EPCR) system in placental 
development and maintenance of pregnancy (Healy et al 1995, Gu et al 
2002). However, the relevance of these mechanisms as regards pregnancy-
associated complications such as recurrent miscarriage (RM) has remained 
unknown. Th us, it is interesting to discover the prevalence of TM and EPCR 
polymorphism in humans, especially in women suff ering from RM.
Despite intensive research, the etiology of preterm delivery and cervical 
insuffi  ciency is far from being solved. Th e interaction between coagulation 
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and infl ammation is well known (Esmon 2003). Th rombin has a key role 
in hemostatic mechanisms and in a variety of activities that result in 
augmentation of the infl ammatory response as well. Th rombin has the 
ability to regulate infl ammatory processes (Esmon 2003). It could play a 
more important role in the pathogenesis of cervical insuffi  ciency and preterm 
delivery than is actually recognized, since it enhances decidual matrix 
metalloproteases (MMPs). Th ese MMPs are strongly linked to premature 
rupture of the membranes (Stephenson et al 2005). On the other hand, 
thrombin itself has a uterotonic eff ect (Elovitz et al 2000, O’Sullivan et al 
2004). Th ese data prompted us to discover if hereditary thrombophilias (with 
increased thrombin formation) are overpresented in women with cervical 
insuffi  ciency and preterm delivery 
Low molecular weight heparin (LMWH) has been shown to be as safe 
and eff ective as unfractionated heparins (UFHs) in the treatment of VTEs in 
nonpregnant patients. Low molecular weight heparin has several advantages 
over UFH, as easier administration and more predictable pharmacokinetics 
lead to less monitoring during treatment. However, at the time when this 
study was conducted, no comparative studies on short- and long-term 
outcome with LMWH and UFH had been published. In the future, it 
will be necessary to discover if we can improve pregnancy outcome with 







































Review of the literature
1. Hemostasis during pregnancy
Normal pregnancy is associated with several changes in all aspects of 
hemostasis. Owing to hormonal changes, increasing concentrations of 
procoagulants, decreased numbers of anticoagulant factors and diminished 
fi brinolytic activity (hemostatic mechanism, appendix I) result in pregnancy 
being a hypercoagulable state in order to prevent maternal hemorrhage aft er 
delivery (Bremme 2003, Brenner 2004). Changes in the clotting system 
are most marked near term and immediately postpartum. However, the 
hypercoagulable state increases the risk of venous thromboembolism. Th is 
hypercoagulabe state returns to normal 4–6 weeks postpartum (Hellgren 
2003).
Th e placenta is an unique organ with dual blood circulations: maternal 
blood fl ows in the intervillous space and decidual blood vessels while fetal 
blood fl ows inside placental villi. Th e hemostatic balance is very sensitive 
in the placenta. Th ere is a continuous low level fi brin production in the 
placenta refl ected in raised levels of plasma D-dimer (Morse 2004, Kline et 
al 2005). Fetal well-being depends critally on the supply and fl ow properties 
of the uteroplacental system (Fig. 1) (Bremme 2003).
Fig. 1. Hemostatic mechanisms in circulation and placenta
Fig 1. Shows increased production of coagulation factors: fi brinogen, prothrombin, 
V, VIII, IX, X, XII, XIII and vWF. Systemic changes in anticoagulantory 
mechanism and local placental hemostatic balance.
ation
0 Luvunotsikko12
During endovascular trophoblast invasion, tissue factor (TF) expression in 
human endometrial stromal cells prevents postimplantational hemorrhage. 
An increased TF expression brought about by estradiol (E2) during 
progestin-induced decidualization has been shown (Lockwood et al 2000). 
Placental cells such as syncytiotrophoblasts are a rich source of TF and they 
are important for the maintenance of hemostasis in the placenta. Erlich et al 
(1999) studied transgenic mice with low expression of TF. Th ey found that 
18% of the mice had fatal postpartum hemorrhage and as many as 40% had 
fatal mid-gestational hemorrhage.
2. Hereditary thrombophilias
Inherited coagupathies are major causes of thromboembolic disease (table 
1). Moreover, the increased risk for maternal complications, hereditary 
thrombophilias mey predispose for pregnancy complication with diff erent 
mechanisms.
2.1 Thrombophilias affecting natural anticoagulation
2.1.1 FV Leiden mutation
Th e most common hereditary thrombophilia is Factor V (FV) Leiden 
mutation, which is found in approximately 5% (2–15%) of Western 
populations (Rees et al 1995). Normally activated protein C inhibits 
coagulation cascade by splitting activated factor V. Th e phenomenon of 
activated protein C (APC) resistance was fi rst described by Dahlbäck et al 
(1993). Th e genetic basis, substitution of adenine for guanine at nucleotide 
1691 of the factor V gene (G1691A), which causes the arginine at residue 
506 of the factor molecule to be replaced by glutamine (Arg506Gln), was 
described a year later by Bertina et al (1994). Th is mutation slows down 
the proteolytic degradation of factor Va by activated protein C, leading to 
increased generation of thrombin (Seligsohn and Lubetsky 2001). Resistance 
to APC has been found in 24–60% of women with pregnancy-associated 
VTE (Hellgren et al 1995, Hallak et al 1997). In the Finnish population the 
prevalence of FV Leiden mutation has been found to be lower (2.1–2.9%) 
than in some other Nordic countries (Kontula et al 1995, Zoller et al 1996, 
Helio et al 1999, Larsen et al 1998, Prochazka et al 2003).
2.1.2 Defi ciencies of Antithrombin, protein C and protein S
Antithrombin defi ciency is the most severe thrombophilic condition 
associated with a 70 to 90 percent lifetime risk of VTE (Girling and de 
Swiet 1998). In family studies women with antithrombin defi eciency, the risk 
for pregnancy-associated VTE without anticoagulation has mentioned as 
high as 40% (Zotz et al 2003). Antithrombin is synthesized in hepatocytes. 
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In addition to its thrombin inhibitory properties, it can also inactivate 
coagulation factors Xa, IXa, VIIa and plasmin, for example (Bombeli et al 
1997). Antithrombin activity is increased by heparin binding up to 1000-
fold (Lockwood 1999). Th ere are several point mutations which can cause 
mostly dominantly inherited antithrombin defi ciencies (Rao et al 1997). 
Two diff erent types of antithrombin defi ciency have been described: 1) low 
functional and immunoreactive antithrombin, and 2) Low functional but 
normal immunoreactive antithrombin. Th e prevalence of antithrombin 
defi ciency is low, 1/600–1/5000 (Tait et al 1994) 
Protein C and its cofactor protein S are produced in the liver and they 
are vitamin K-dependent enzymes. Activated protein C is an important 
part of the inhibitory pathway of the coagulation mechanism. Defi ciency of 
protein C is mainly of two types: 1) both immunoreactive and functionally 
active protein C are reduced, and 2) immunoreactive levels are normal 
but activity is reduced (Lockwood 1999). Th ere is also a wide variety of 
genes and mutations associated with protein C. Th e prevalence of protein 
C defi ciency is low (0.2–0.5%), but type II defi ciency is relatively common 
in Finland, accounting for approximately one half of all protein C defects 
and, interestingly, virtually all cases with type II defi ciency have been found 
to carry one single mutation, W380G (Levo et al 2000). Th e prevalence of 
protein S defi ciency is approximately the same as that of protein C and both 
show autosomal dominant inheritance. Protein S defi ciency is of three types: 
1) reduced total and free protein S, 2) normal protein S but reduced APC 
cofactor activity, and 3) normal total protein S but reduced free protein S levels 
(Lockwood 1999). Th e lifetime risk of VTE associated with either protein C 
or S defi ciency is about 50% (Allaart et al 1993, Gouault-Heilmann et al 1994) 
and both are associated with adverse pregnancy outcome (Robertson et al 
2006). Protein S levels are decreased during normal pregnancy, and therefore 
diagnoses of protein S defi ciences should be made outside pregnancy.
2.2 Thrombophilias affecting procoagulants 
2.2.1 Prothrombin gene 20210A mutation
Poort et al (1996) described a mutation in the 3´ untranslated region of 
the prothrombin gene. Th e mutation, the result of a guanine to adenine 
substitution at position 20210, leads to signifi cantly elevated plasma 
prothrombin levels. Th e mutation is present in 1–2% of the healthy population 
and it increases the risk of VTE 3-fold (Rosendaal et al 1998) (table 1). 
Th ere are no studies concerning the prevalence of prothrombin mutation 
in Finland. Among patients with their fi rst episode of VTE, prothrombin 
mutation has been found in 6% (Zotz et al 2003).
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2.2.2 High level of factor VIII
Th e signifi cance of a high level of FVIII is unclear, but it is evident that 
high levels increase the risk of deep venous thrombosis (Kraaijenhagen et 
al 2000). A constantly high level of FVIII (> 150 IU/dL) is considered to 
be abnormal. Most instances of high levels of FVIII are acquired and/or 
transient, appearing in cases of infection and estrogen treatment, but there 
is also a hereditary form (Bank et al 2005).
2.2.3 Hyperhomocystinemia 
Hyperhomocystinemia is known to cause direct endothelial injury through 
increased oxidative stress (Rao et al 1997), to induce impairment in 
endothelial synthesis of vasodilatory substances, to increase the expression of 
procoagulants, and increase platelet aggregation (Rao et al 1997). Most mild 
or moderate forms of hyperhomocystinemia are the result of homozygosity 
of the 667C-T methylene tetrahydrofolate reductase (MTHFR) mutation, 
the prevalence of which among Europeans is about 11% (Molloy et al 1997). 
Although hyperhomocystinemia is a risk factor of arteriosclerosis, its role 
solely in pregnancy complications is not defi ned (Rey et al 2003, Jääskeläinen 
et al 2006)
Th ere are numerous of studies on polymorphism of coagulation factors 
(e.g. TF, TFPI, fi brinogen, XII, XIII), but the clinical relevance has not been 
ascertained (Bertina 2001).
Table 1. Relative risk and probability of pregnancy-associated thrombosis in 
regard to hereditary coagulation factors in unselected women (without familial 
thrombophilia)
Genetic defect  Relative risk Probability of  
  (95% CI) pregnancy- 
   associated VTE
FV Leiden mutation heterozygous 5.3 (3.7–7.6)  0.26%  
 homozygous 25.4 (8.8–66)  1.5%
Prothrombin G20210A mutation 6.1 (3.4–11.2) 0.37%
Protein C defi ciency < 50% 13.0 (1.4–123) 0.8%
Antithrombin defi ciency< 85% 3.0 (1.1–8.7)  0.19%
       < 60% 119  7.2%
Protein S defi ciency  Not known  Not known
Adapted from (Zotz et al 2003).
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3. Acquired thrombophilias
Hypercoagulable state can be also acquired due to f.ex.infection, medication 
and change in physiologic status as occurs with pregnancy. Acquired 
thrombophilias increases risk both venous and arterial side thrombosis. 
Th e major causes of acquired thrombophilias is shown in table 2.










Acquired defi ciency of protein C, S or antithrombin
3.1. Activated protein C (APC) resistance
Th e phenomenon of activated protein C resistance is mainly explained by FV 
Leiden mutation, as previously described. However, APC resistance has also 
been associated with certain factors such as antiphospholipid antibodies and 
cancer (Bokarewa et al 1995, Haim et al 2001). Hormonal changes during 
pregnancy, and oral contraceptives, can induce APC resistance, mainly via 
changes in protein S levels (Cumming et al 1995, Castoldi et al 2004). 
3.2. Essential thrombocythaemia
Essential thrombocythaemia is a chronic myeloproliferative disorder. According 
to the conventional criterion for thrombocythaemia, the platelet count is above 
600 × 109/L (Lengfelder et al 1998). Causes of reactive thrombocytosis are 
infl ammation, infection hemorrhage and iron defi ciency. Th rombocythemia 
increases the risk of thrombosis in high-risk patients (elderly, earlier VTE), 
whereas the risk of thrombosis in low-risk subjects is similar to that observed 
in the normal healthy population (Ruggeri et al 1998). 
3.3. Antiphospholipid syndrome
Antiphospholipid syndrome (aPS) is an autoimmune disorder in which 
patients have antibodies against phospholipid structures in their blood and 
at least one clinical manifestation such as adverse pregnancy outcome or 
thromboembolism (primary aPS). Antiphospholipid antibodies (aPL) are 
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found among 1–5% of young healthy people (Petri 2000). Antiphospholipid 
antibodies can be present in association with some autoimmune conditions 
(secondary aPS), especially systemic lupus erythematosus (SLE). Among 
such patients aPLs have been found in 30% (Love and Santoro 1990). 
Th e clinical manifestations related to these antibodies include both 
arterial and venous thrombosis, spontaneous pregnancy losses and oft en 
thrombocytopenia. Th e results of a recent meta-analysis showed signifi cant 
associations between aPLs and both early and late fetal loss and an increased 
risk of preeclampsia (Robertson et al 2006). Th e etiology associated with 
these antibodies is unclear and even their antigenic targets are not fully 
established. Th us, aPS is classifi ed as an autoimmune disorder. Some bacterial 
infections such as syphilis and Lyme disease can also induce aPL production 
(Rand 2003). Th e fi rst observation of a false-positive serological test for 
syphilis was made by Moore and Mohr in 1952, and later Harris et al (1987) 
and Hughes (1985) also described this clinical phenomenon. Th e diagnostic 
criterias of aPS (Miyakis et al 2006) are presented in table 3. 
Table 3. Diagnostic criteria of aPS
1. Clinical history of vascular thrombosis or pregnancy morbidity.
2. Laboratory evidence of Lupus Anticoagulant (LA) or at least a medium titer of IgM 
or IgG anticardiolipin antibodies (aCLs), or specifi c anti-β2 glycoprotein I antibodies. 
Th e abnormalities should be present twice, at least six weeks apart.
Th ere are seasonal changes in the prevalence of aPL in the normal population, 
with a higher prevalence in the winter time compared with summer (perhaps 
related to viral infections, which have been connected to a rise in aCL). 
However, correlation of the seasonal prevalence of aPL and VTE has not 
been established (Luong et al 2001). Although antiphospholipid syndrome 
has been classifi ed as an acquired thrombophilia, familial clustering of 
raised of aPL antibodies exists (Hellan et al. 1998) and HLA linkage has 
been shown (Sanchez et al 2004).
Th e pathogenesis of aPS is not clear but antigenic targets and cofactors 
are known. Anti- β2-glycoprotein I is a highly glycosylated single-chain 
protein that may have a role in recognition of anionic phospholipids by 
aPLs (Schultz 1997). Th e physiological function of anti-β2-glycoprotein I 
is not fully understood and its role as an independent risk factor of 
thrombosis is unclear (Rand 2002, de Groot and Derksen 2005). Other 
cofactors associated with aPLs such as prothrombin, FV, proteins C and S, 
high and low molecular weight kininogen and annexins have been described 
(de Groot et al 1996). Th romboxane dominance has also been shown to 
be related to aPL in pregnant women with SLE. Th is may contribute to 
adverse pregnancy outcome (Kaaja et al 1993b). Moreover, in addition 
to the established procoagulative properties of aPL, there is evidence that 
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aPL can directly interfere with decidual endovascular trophoblast invasion 
(Sebire et al 2002). 
Accumulated data concerning the pathogenetic mechanisms associated 
with aPLs is shown in table 4. Th ere are many biological processes in which 
aPLs seem to play role but it is diffi  cult to determine whether they are 
clinically relevant or not.
Table 4. Suggested thrombotic mechanisms of aPLs
Interference with a phospholipid- or other polyanionic-dependent antithrombotic 
mechanism
Disruption of the annexin V shield
Interference with protein C
aPL binding with proteins C and S
inhibition of protein C
acquired protein C resistance
Inhibition of tissue factor pathway inhibitor (TFPI)
Impairment of phospholipid-mediated autoactivation of Factor XII and reduced 
fi brinolysis
Inhibition of heparin-antithrombin complexes
Promotion of tissue factor expression/synthesis on monocytes and endothelial cells
Vascular injury/stimulation of apoptosis
Injury to endothelium
Induction of apoptosis of vascular cells
Release of membrane-bound microparticles 
Promotion of cellular adhesion to vascular surfaces
Stimulation of platelet function
Platelet activation: increased thromboxane production
Release of membrane-bound microparticles 
Others
Increase in endothelin-1
Cross-reactivity to oxidised LDL
Increase in PAI-1
Adapted from J. Rand (2002)
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4. The role of annexins IV and V
Annexins are a family of structurally related proteins which all have high 
affi nity to negatively charged anionic phospholipids (PLs) in the blood vessels, 
acting in a calcium ion-dependent manner. The best-known annexin, annexin 
V, has anticoagulant properties and the capacity to displace coagulation 
factors from anionic phospholipid surfaces (Rand et al 1997).
In the placenta, annexin V is localized on the apical surfaces of the 
syncytiotrophoblasts (STBs) and it is necessary for the maintenance of 
placental development and its integrity (Wang et al 1999). Wang et al 
(1999) infused polyclonal anti-annexin V antibodies into pregnant mice, 
causing placental infarction and pregnancy wastage. The physiological 
function of annexin V is still not fully understood. However, it is known 
that it has anticoagulant properties and it is speculated to have a role in 
placental apoptosis (Bonet et al 1992, Krikun et al 1994). Anti-annexin 
V antibodies have been detected in subjects with an elevated incidence of 
intrauterine fetal loss, preeclampsia and arterial and venous thromboses 
(Matsuda et al 1994a, Kaburaki et al 1997, Matsubayashi et al 2001). 
Di Simone et al (2001) speculated that anti-annexin V antibodies could 
affect embryo implantation and worsen pregnancy outcome by way of 
syncytiotrophoblast apoptosis and inhibition of trophoblastic gonadotropin 
secretion (Matsuda et al 1994b, Kaburaki et al 1997, Wang et al 1999). 
Antiphospholipid antibodies are known to promote coagulation activation 
via many mechanisms (table 4). One of the proposed mechanisms could 
be displacement of annexin V, with anticoagulant properties, from the 
surfaces of STBs by antiphospholipid antibodies (Rand et al 1994, Rand 
et al 1997), which may lead to activation of coagulation complexes. 
Fig. 2. Pathophysiological mechanisms of annexin on syncytiotrophoblasts surfaces 
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Compared with annexin V, much less is known about annexin IV. 
Annexin IV expression has been found in the basal layer of STBs in the 
placenta (Masuda et al 2004). Annexin IV seems to enter the maternal 
blood circulation just aft er delivery and it has been speculated to have a 
preventative role in DIC (Masuda et al 2004).
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5. Venous thromboembolic disease 
Venous thromboembolism (VTE) represent the greatest single cause of 
death in pregnant women in developed countries (Gates 2000). Deep venous 
thrombosis and pulmonary embolism are two diff erent manifestations of one 
disease (Ginsberg 1996). Pulmonary embolism (PE) is estimated to cause 50 
maternal deaths in pregnancy every year in the United Kingdom (Greer 1999). 
Th e incidence of VTEs has been estimated to be 1/1000–1/2000 pregnancies, 
which is 5–10 times higher than the incidence in nonpregnant women 
(1/10 000) (Greer 1997). In Finland, at least 2–7 deliveries with associated 
pulmonary embolism are confi rmed every year. Venous thromboembolism, 
overall, are the main cause of maternal mortality (2/100 000 live births) 
(Gissler M, Finnish Birth Register, personal communication). Th e etiology 
of deep venous thrombosis during pregnancy is multifactorial and common 
risk factors are shown in table 5.
Table 5. Major risk factors of DVT during pregnancy
Age above 35 years
Obesity 
Immobilization 
Operative delivery, especially cesarean section
Th rombophilias 
Infection
All factors of Virchow´s triad (hypercoagulability, venous stasis and 
vascular damage) occur during pregnancy. As a result of anatomic factors 
during pregnancy, blood fl ow velocity is reduced in the femoral veins by 
approximately 50% from 25 weeks of gestation to the end of pregnancy 
(Macklon et al 1997) and it normalizes to the nonpregnant level around six 
weeks aft er delivery (Lindhagen et al 1986). Left -side over-presentation has 
also been described in pregnancy-associated deep venous thrombosis. Th is 
is possible because during pregnancy, the left  iliac vein is compressed by the 
left  iliac artery and ovarian arteries (Cockett et al 1967). Endothelial damage 
during operative delivery may be a trigger for a cascade that leads to a highly 
increased risk of venous thromboembolism. Th e highest risk periods for VTE 
are during the late third trimester and immediately postpartum, but almost 
30% of cases of VTE have been reported in the fi rst trimester (Ginsberg et 
al 1992, Toglia and Weg 1996, Gherman et al 1999).
Deep venous thromboses related to pregnancy are oft en massive and 
therefore the risk of developing venous insuffi  ciency or post-thrombotic 
syndrome in the long term may be higher than in the nonpregnant state 
(Holmström et al 1999). Although antepartum VTE complications are 
more common, it has been suggested that puerperal VTE events are 
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underestimated because these maternal complications are oft en treated 
in non-obstetric hospitals. 
Upper extremity deep venous thrombosis (UEDVT) is uncommon 
and represents only 11% of all diagnosed DVTs (Joff e et al 2004). Most 
oft en, UEDVT is associated with mechanical or anatomic compression 
or obstruction or severe thrombophilic disorders such as antithrombin 
defi ciency or antiphospholipid syndrome (Prandoni et al 1997, Joff e et al 
2004). Growing evidence, mainly based on case reports, has shown that the risk 
of UEDVT has increased in connection with the use of assisted reproductive 
technology (ART), especially if ART cycles have been complicated by ovarian 
hyperstimulation syndrome (OHSS) (Chan and Ginsberg 2006, Nelson 
and Greer 2006). Ovarian induction and maturation with gonadotropin-
releasing analogs cause marked procoagulant changes in the hemostatic and 
fi brinolytic systems (Aune et al 1991). In severe OHSS (1–2% of cases) is 
oft en characterized by ascites, hypoalbuminemia and reduced intravascular 
volume, which are additional risk factors for thrombosis (Kaaja et al 1989, 
Aune et al 1991). Although ART increases the risk of thrombosis, screening 
for thrombophilias is not cost-eff ective (Fabregues et al 2004), but the risk 
of thrombosis should be evaluated individually.
Diagnosis of a VTE can be diffi  cult because many of the classic symptoms 
such as dyspnea, tachypnea, leg swelling and tachycardia have also been 
associated with normal pregnancy (Garcia-Rio et al 1996). Clinical diagnosis of 
DVT and PE is unreliable. In nonpregnant patients, DVT has been confi rmed 
by objective methods in only about 30% of suspected cases (Ginsberg 1996). 
In a large retrospective study (Refuerzo et al 2003) conducted in pregnant 
patients with suspected PE, it was shown that symptoms did not diff er in 
patients with confi rmed PE compared with those without PE. Pulmonary 
embolism develops in approximately 15–24% of patients with untreated 
deep vein thrombosis (Rutherford and Phelan 1986, Gherman et al 1999, 
Winer-Muram et al 2002).
In nonpregnant subjects, D-dimer, a specifi c degradation product of fi brin, 
has been used as a diagnostic tool of DVT and PE (Bounameaux et al 1994). D-
dimer has a good negative predictive value as regards excluding DVT and PE 
outside pregnancy (Bounameaux et al 1994). During pregnancy, its specifi city 
is low, which limits its use as a diagnostic tool (Proietti et al 1991, Nolan et al 
1993, Francalanci et al 1995a, Francalanci et al 1995b). Contrast venography 
remains the “gold standard” test for the diagnosis of lower extremity DVT 
(Rabinov and Paulin 1972, Hull et al 1983). However, venography is invasive 
and exposes the patient to radiation, so it is not optimal for pregnant subjects. 
Th us, diagnosis of deep venous thrombosis in symptomatic subjects is based 
on the non-invasive compression ultrasound (CUS) test (Heijboer et al 1993). 
In cases of symptomatic patients with suspected calf DVT, normal CUS 
should be repeated aft er 2–3 days. If iliac DVT is suspected, pulsed Doppler 
ultrasonography can help in diagnosing DVT.
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When PE is suspected, a radiological test should be performed, because 
the harmful eff ects of radiation are minimal compared with the consequences 
of a missed diagnosis of PE (Ginsberg et al 1989a). Pulmonary spiral 
computer tomography (CT) scans of the lungs has been increasingly used 
in the diagnosis of PE.
5.1 Treatment of venous thromboembolism during pregnancy
Non-pregnant patients with deep venous thrombosis are usually treated 
in the acute phase with low molecular weight heparin (LMWH) given 
subcutaneously (Holmström et al 1999). Low molecular weight heparin 
has been shown to be as safe and eff ective as unfractionated heparin in the 
treatment of VTE (Holmström et al 1999, Dolovich et al 2000). However, in 
many countries UHF is still used for treatment of DVT during pregnancy 
because of long experience of its eff ectiveness, and monitoring (Ginsberg 
et al 1989b, Ginsberg et al 1989c, Ensom and Stephenson 2004). Th e 
anticoagulation eff ect of UFH can be neutralized quickly with protamine 
(Hirsh and Raschke 2004). 
Fig. 3. Eff ects of heparins in coagulation cascade









FV                 FVa
Fibrinogen Fibrin
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Table 6. Properties of unfractionated heparin and LMWH, Modifi ed from Hirsh et al (2001) 
Unfractionated heparin Low molecular weight heparin
-molecular weight 3000–30 000 (mean 15 000) -molecular weight 1000–10 000 (mean 5000)   
 approximately 45 monosaccharide chains -longer clearance through renal route
-anticoagulant profi le and clearance depends on chain  -lower binding to proteins and cells
  length of molecule, higher cleared more rapidly -the risk of HIT and osteoporosis is much 
-binds to platelets (PF4), inhibits aggregation   lower than with unfractionated heparin
-increases vessel permeability -more stable pharmacokinetics, self-administration
-suppresses osteoblast formation, activates osteoclasts -favorable IIa to FXa ratio
On the basis of earlier results, low molecular weight heparin (LMWH) 
(Forestier et al 1984, Forestier et al 1992), like unfractionated heparin (UFH) 
(Flessa et al 1965), does not cross the placenta and is at present considered to 
be the drug of choice for the prophylaxis of VTEs during pregnancy (Greer 
and De Swiet 1993, Toglia and Weg 1996, Pettilä et al 1999). Plasma levels of 
UFH vary depending on the degree of binding to proteins in plasma and on the 
endothelium (Glimelius et al 1978) and UFH requires more monitoring and 
dose adjustments. Th us LMWH has several advantages over unfractionated 
heparin such as longer half-life (Weitz 1997), and more stable and predictable 
pharmacokinetics (Greer 1999), which makes possible subcutaneous once 
or twice daily self-administration, with minimal laboratory monitoring. 
Long-term use of UFH is associated with signifi cant maternal side eff ects 
during pregnancy such as increased risks of osteoporosis and symptomatic 
vertebral fractures (2–3%), heparin-induced thrombocytopenia (HIT), 
and allergy (Nelson-Piercy 1997). Low molecular weight heparin has been 
shown to be safer than UFH as regards HIT (Warkentin et al 1995). Several 
investigators have also shown no signifi cant eff ect on bone mineral density 
when prophylactic doses of LMWH are used (Shefras and Farquharson 
1996, Sanson et al 1999, Pettilä et al 2002).
Up to now, there have been no randomized studies in which UFH and 
LMWH have been compared in the treatment of DVT during pregnancy. 
Experience of the use of LMWH for prophylaxis has also encouraged its 
use in the treatment of DVT. In Finland there are two LMWHs (enoxaparine 
and dalteparin) available for VTE prophylaxis and treatment. They have 
both been used during pregnancy.
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5.2 Long-term outcome of venous thromboembolism during 
pregnancy
In addition to a lack of controlled randomized prospective trials concerning 
the management of VTE during pregnancy, there are few data on the long-
term outcome of pregnancy-related DVT. Post-thrombotic syndrome (PTS) 
is chronic complication of DVT. Th e reported incidence of PTS varies 
from 20% to 100% owing to initially diff erent defi nitions of the syndrome 
(Gjores 1956, O’Donnell et al 1977) and lack of diagnostic criteria (Kahn 
and Ginsberg 2002). Clinical symptoms of PTS are pain, swelling, pruritus, 
eczematous skin change, development of secondary varicose veins and 
even ulceration of the leg (Immelman and Jeff ery 1984). Th ere are no gold 
standards for the diagnosis of PTS but it should be based on the presence of 
typical symptoms. Confi rming venous refl ux by means of ultrasonography 
may help diagnosis (Kahn and Ginsberg 2002). A clear correlation between 
size, degree of occlusion and location of the initial thrombus has not been 
documented (Browse et al 1980, Prandoni et al 1996), but there is evidence 
for a higher rate of PTS aft er proximal compared with distal DVT (Lindner 
et al 1986, Holmström et al 1999, Mohr et al 2000). According to Janssen et 
al (1997), only 10–30% of patients are symptom-free aft er iliac DVT. Th e 
results have been disputed in another study (Philbrick and Becker 1988), 
but recurrent DVT has been confi rmed to be a risk factor of PTS in many 
studies (Prandoni et al 1996, McColl et al 2000). Th ere are also studies that 
suggest that high BMI could be an independent risk factor of PTS (Biguzzi 
et al 1998, Ageno et al 2003).
Deep venous thrombosis during pregnancy is oft en massive and proximal, 
and the risk of PTS could be expected to be higher than aft er DVT outside 
pregnancy (Greer and De Swiet 1993). Th ere are few studies on this issue. 
McColl et al (2000) described a 79% incidence of post-thrombotic syndrome 
in women who suff ered from DVT during pregnancy. As post-thrombotic 
symptoms in young women may cause impairment in the quality of life of 
otherwise healthy people, it is very important to evaluate the impact of initial 
treatment of DVT with subcutaneous LMWH compared with the standard 
therapy with intravenous UFH.
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6. Thrombophilias and pregnancy complications
Th ere is growing evidence that women with thrombophilia are at an increased 
risk of several severe obstetric complications in addition to VTEs. Th ese 
include recurrent miscarriage (RM), preeclampsia, intrauterine growth 
restriction (IUGR), unexplained intrauterine fetal death (stillbirth) and 
placental abruption (Kupferminc 2003, Rey et al 2003, Dudding and Attia 
2004). Th rombotic factors could operate at the level of the placenta aft er 
gestational week 8, when the placental circulation maintains pregnancy. 
However, aPLs may have pathogenetic mechanisms other than those related 
to the thrombotic process, such as apoptosis and the ability to interfere with 
trophoblast diff erentiation (Bonet et al 1992, Sebire et al 2002, Quenby et al 
2005). Maternal thrombophilia together with natural prothrombotic changes 
during pregnancy may shift  the hemostatic balance towards thrombotic changes 
in placental capillaries, leading to inadequate fetomaternal circulation and 
decreased placental perfusion (Khong et al 1987, Roberts et al 1989, Shanklin 
and Sibai 1989, Salafi a et al 1995, Redman et al 1999). Retrospective case-
control studies suggest a strong causal relationship between thrombophilias 
and recurrent miscarriages (Robertson et al 2006), although confl icting data 
still exist (Infante-Rivard et al 2005). Th ere are also histological studies of the 
placenta that show a relationship between pregnancy complications, placental 
pathology and maternal thrombophilia (Arias et al 1998, Many et al 2001), 
although there is also confl icting data which failed to show any diff erences 
in obstetric complications in regard to specifi c histologic fi ndings in women 
with and without thrombophilia (Mousa and Alfi revic 2000). One major 
problem is the heterogeneity and small sizes of study populations. Moreover, 
inclusion criteria and even outcomes vary, resulting in certain limitations as 
regards the conclusions. It is clear that the etiology of these severe obstetric 
complications is multifactorial, and it seems evident that thrombophilia has an 
additional role in the pathogenesis of these complications, as recently shown 
in a Finnish study (Järvenpää et al 2006). 
Although thrombophilias may be harmful during pregnancy, they also 
have benefi cial eff ects. It has been shown that FV Leiden carriers have less 
blood loss during delivery (Lindqvist et al 1998) and even less menstrual 
bleeding compared with non-carriers (Lindqvist et al 2001). Th ere are some 
studies concerning the association between thrombophilic mutations and 
fecundity. Of interest is the recent study by van Dunne et al (2006) showing 
that fecundity is increased in male but not in female FV Leiden mutation 
carriers. Th ere are speculations concerning a link between the FV Leiden 
gene and a fertility gene that may potentially aff ect sperm count and motility. 
In one study the implantation rate was reported to be higher if either the 
mother or the child carried the FV Leiden mutation (Gopel et al 2001), but 
contradictory results indicating an increased number of failures aft er IVF 
treatment of thrombophilic women have also been shown (Azem et al 2004, 
Qublan et al 2006).
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6.1 Recurrent miscarriage and fetal loss
Defi nitions of recurrent miscarriage (RM) vary but generally it has been 
characterized as at least three consecutive miscarriages in the fi rst or 
second trimester of pregnancy (upper limit 22 weeks of gestation, WHO) 
(Tulppala and Ylikorkala 1999). Late fetal loss (stillbirth) has been defi ned 
as intrauterine fetal death beyond 22 weeks of gestation. 
Every tenth pregnancy ends in miscarriage and one tenth of these 
miscarriages are recurrent (≥ three consecutive miscarriages) meaning that 
1% of all pregnancies end in recurrent miscarriage (Tulppala et al 1993, Li 
et al 2002). Some clinicians defi ne recurrent miscarriage as two or more 
consecutive miscarriages, which increases the number of cases from 1% to 5% 
(Hogge et al 2003). Th e risk of miscarriage increases with maternal age (Nybo 
Andersen et al 2000). Etiological factors of RM are shown in table 7.
Table 7. Possible etiological factors of recurrent miscarriage




Endocrine abnormalities (luteal insuffi  ciency? PCO?, insulin resistance?, thyroid 
dysfunction?)
Immune dysfunction (unfavorable cytokine shift  Th 1→ Th 2, autoantibodies?)
Endometrial responsiveness?
Fetal chromosomal defects have been suggested to be the most common 
reason for sporadic miscarriage, accounting for as much as 50% of all 
miscarriages (Stephenson et al 2002). On the other hand, the frequency of 
a normal embryonic karyotype increases with the number of miscarriages, 
this indicating a more important role of maternal factors in pregnancy 
failure (Ogasawara et al 2000, Sullivan et al 2004). Both retrospective and 
prospective studies show that the risk of unsuccesful pregnancy outcome 
in the following pregnancy increases with the number miscarriages, being 
40–45% aft er three miscarriages (Regan et al 1989, Lee and Silver 2000, 
Nybo Andersen et al 2000)
Antiphospholipid syndrome is a well-recognized cause of RM and has 
been reported in 7–42% of women with RM (Greaves et al 2000). In addition 
to aPL antibodies, there is also a heterogeneous groups of hemostasis-related 
autoantibodies (e.g. anti-prothrombin, anti-β2 glycoprotein-1 antibody, 
anti-phosphatidylserine, phosphatidylethanolamine, and anti-annexin V) 
which can locally promote hypercoagulation, and interfere with trophoblast 
invasion and growth (Shoenfeld and Blank 2004). 
On the basis of the results of small retrospective studies, and a review, 
it has been suggested that also essential thrombocythaemia could be a risk 
factor of miscarriage (Elliott and Teff eri 2003, Niittyvuopio et al 2004).
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Growing evidence from case-control studies and recent meta-analyses 
has shown an association between recurrent miscarriage and some, but 
not all, thrombophilias (table 8). Th e association seems to be even stronger 
with late fetal losses (2nd or 3rd trimester) (Rey et al 2003, Kujovich 2004, 
Robertson et al 2004).
Table 8. Th rombophilia-associated fetal losses 
Thrombophilia Recurrent miscarriage Late fetal loss
FV Leiden mutation + ++
Prothrombin G20210A mutation ++ ++ 
Protein C defi ciency ? ?
Protein S defi ciency ? ++
Antithrombin defi ciency ? ?
MTFHR homozygosity +/- +/-
Anticardiolipin antibodies ++ ++
Lupus anticoagulant ++ ++
Although meta-analyses have partly failed to show an association between 
protein C and S defi ciency, antithrombin defi ciency and fetal losses, these 
defi ciencies of the anticoagulative mechanism are capable of causing a severe 
thrombophilic state and they markedly increase the risk of a VTE (Robertson 
et al 2004). Th us, we can assume that they may have a role in the etiology of 
RM and fetal loss. On the other hand, in some cases RM could be related to 
low grade thrombophilias known not to be associated with a VTE (e.g. low 
positive antiphospholipid antibody levels) (Rai et al 1997, Pattison et al 2000, 
Farquharson et al 2002 ). Th is highlights the special role of the placenta as a 
most sensitive organ in which a thrombotic event may manifest itself.
6.2 Preeclampsia
Preeclampsia aff ects approximately 5% of singleton pregnancies. Its etiology is 
still poorly understood. It is characterized by an abnormal vascular response 
to placentation in that there is increased systemic vascular resistance (high 
blood pressure), enhanced platelet aggregation, activation of the coagulation 
system, and endothelial cell dysfunction (edema, proteinuria) (Sibai 2005). 
Th e risk factors of preeclampsia are described in table 9.
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Table 9. Risk factors of preeclampsia (couple-related risks) (Sibai et al 2005)
Primipaternity
Pregnancies aft er donor insemination, oocyte donation, embryo donation
Protective eff ect of partner change in the case of previous preeclamptic pregnancy
Maternal or pregnancy-related risk factors
Extremes of maternal age
Multifetal gestation
Preeclampsia in a previous pregnancy
Chronic hypertension or renal disease
Rheumatic disease
Maternal low birth weight





Family history of preeclampsia
Smoking (reduced risk)
Hydropic degeneration of the placenta
Gestational hypertension (GH) without proteinuria can represent a mixture 
of preeclampsia and a heterogeneous group of preexisting hypertensive 
disorders aff ecting up to 20% of pregnancies (Morrison et al 2002). Th e 
fi rst report of an association between early onset (before 34 weeks of 
gestation) or severe preeclampsia and aPL was described by Branch et 
al (1989). Later, Dekker et al (1995) reported an association between an 
inherited thrombophilic mutation and preeclampsia. Most studies later 
showed an association between thrombophilia and early onset or severe (< 
34th week of gestation or proteinuria > 5 g/day) preeclampsia but not mild 
or term preeclampsia (Morrison et al 2002, Sibai et al 2005, Sibai 2005, 
Robertson et al 2006). Recent meta-analyses (Robertson et al 2006) have 
indicated that preeclampsia is signifi cantly associated with FV Leiden and 
prothrombin mutations, anticardiolipin antibodies, MTFHR homozygosity 
and hyperhomocystinemia, whereas protein S, protein C, and antithrombin 
defi ciency are not signifi cant risk factors. In a recent large case-control study, 
Mello et al (2005b) showed not only an association between thrombophilia 
and severe preeclampsia but also a tendency towards increased risks of 
maternal complications such as early onset of disease (< 28 weeks of 
gestation), placental abruption, disseminated intravascular coagulation 
(DIC) and acute renal failure.
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6.3 Intrauterine growth restriction
Same vasculopathic fi ndings related to preeclampsia may also be seen in 
IUGR. However, the association between thrombophilic disorders and 
IUGR is weaker than in preeclampsia and the evidence is not indisputable 
(Infante-Rivard et al 2002, Verspyck et al 2004). Th e etiology of IUGR is 
multifactorial, but thrombophilia may have an additional role. A diagnosis 
of IUGR might be erroneous if only birth weight for gestational age is used. 
Individual neonates in the low centile groups might not be aff ected by IUGR 
but most neonates are constitutionally small (Mamelle et al 2001, Mamelle 
et al 2006). In such cases of small-for-gestational age (SGA) infants later 
prognosis is normal. However, thrombophilia seems to increase the risk 
of IUGR, although the only signifi cant association has been found with 
anticardiolipin antibodies (Robertson et al 2006).
6.4 Placental abruption
Th e incidence of placental abruption in Finland is 0.42% of pregnancies 
(Tikkanen et al 2006). General risk factors are maternal and paternal 
smoking, use of alcohol, placenta previa, preeclampsia, and chorioamnionitis 
(Tikkanen et al 2006). Placental abruption has also been reported to be more 
prevalent in thrombophilic pregnancies (Kupferminc et al 1999) and in 
women with a family history of venous thromboembolism (Prochazka et al 
2003). Some Finnish studies have shown no association between FV Leiden 
mutation or MTFHR polymorphism and placental abruption (Jääskeläinen 
et al 2004, Jääskeläinen et al 2006). However, a recent meta-analysis showed 
that FV Leiden mutation and prothrombin mutation were associated with 
an increased risk of placental abruption (Robertson et al 2006).
Current evidence shows that there are similar vasculopathic fi ndings in 
preeclampsia, IUGR, fetal loss and placental abruption, and thrombophilia 
seems to play a role in the etiology of these complications. Although 
the etiology is multifactorial, the association between thrombophilia 
and placental pregnancy complications seems to be particularly strong, 
especially in early-onset and severe forms of complications (Lockwood 
2002). Th rombophilias have also been associated with a severe form of 
preeclampsia, HELLP (hemolysis-elevated liver enzymes-low platelet) 
(Bozzo et al 2001).
6.5 Prevention of thrombophilia-associated pregnancy 
complications
Most of the data on interventional studies to prevent thrombophilia-associated 
pregnancy complications concerns RM. However, we must be cautious when 
interpreting this data. Th e study populations are heterogeneous and small 
and the types of thrombophilia are divergent. Th ere is a lack of randomized 
trials, making comparisons inconclusive. Some small studies (Kutteh 1996, 
Rai et al 1997) showed that unfractionated heparin and acetosalisylic acid 
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(ASA) can improve pregnancy outcome in patients with RM and aPLs 
compared with ASA alone. It seems that patients with aPLs and RM benefi t 
from antithrombotic therapy (Empson et al 2005). However, Farquharson et 
al (2002) found no benefi cial eff ect of LMWH/ASA compared with aspirin 
alone in aPL-positive women with RM.
Th ere are some non-randomized observational studies (Brenner et al 
2000, Carp et al 2003) in which improvement of pregnancy outcome with 
LMWH prophylaxis has been shown. Gris et al (2004) showed in their 
comparative trial that LMWH treatment is superior to ASA in patients 
with a history of single miscarriage and thrombophilia. Recently, Dolitzky 
et al (2006) compared enoxaparin and ASA in the prophylaxis of RM of 
unknown etiology and showed no signifi cant diff erences between these 
treatments. Successful pregnancy outcomes were 94% (LMWH) vs. 81% 
(ASA). Th e results in both groups were better than the spontaneous success 
rates mentioned in the literature overall. Because intervention was started 
at 6–12 weeks of pregnancy, aft er a viable fetus was confi rmed, the study 
population was already selected and biased.
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 Study patients Intervention Start of treatment Controls Results
Dolitzky et al 2006 n=104 54 enoxaparin 6–12 weeks of 54/50 82% vs 84%
 RM (≥3), unknown  vs gestation  NS
 etiology, excluded 50 ASA 100mg
 thrombophilia
Tzafettas et al 2005 RM (≥3) ASA 80mg and confi rmed viable  no  83% vs 85%
 24 thrombophilic  LMWH fraxiparine pregnancy  NS
 hered/acquired and
 27 non-thrombophilic
Noble et al 2005 n=50, RM (≥3) LMWH enoxaparin  positive pregnancy 25/25 84% vs 80%
 aPL positive ASA 81mg test  NS
 GPL≥20, MPL≥20 vs
 phosphatidylserine ab, LAC  UFH
  ASA 81mg
Gris et al 2004 n=160 80 LMWH enoxaparin  8 weeks gestation no 86% vs 29%
 single fetal loss  vs   S
 and thrombophilia 80 ASA 100mg 
Carp et al 2003 n=85, RM (≥3) 37 enoxaparin 40mg confi rmed  48 no  70% vs 44%
 thrombophilic vs pregnancy treatment S
 hered/acquired 48 no treatment
Farquharson et al 2002 n=95, RM (≥3) 51 LMWH 5000 IU before 12 weeks no 78% vs 72%
 aPL positive + ASA 75mg  of gestation  NS
 GPL≥9, MPL≥5 vs
 LAC 47 ASA 75mg
Brenner et al 2000 RM (≥3) LMWH enoxaparin + confi rmed viable no 75%
 50 thrombophilic low dose ASA for aPL  pregnancy
 hered/aqcuired
Pattison et al 2000 RM (≥3), n=20 ASA 75 mg confi rmed pregnancy 20/20 85% vs 80%
 aPL positive vs   NS
 GPL≥5, MPL≥5 placebo
 LAC
Rai et al 1997 RM (≥3), n=90 UFH 5000 IU x 2 confi rmed fetal heart 45/45 71% vs 42%
 aPL positive + ASA 75mg n=45 beats  S
 GPL≥5, MPL≥3 vs
 LAC ASA 75mg n=45
 
Kutteh 1996 RM (≥3) n=50 UFH 5000 IU x 2 confi rmed pregnancy 25/25 80% vs 44%
 aCL ≥27 GPL ASA 81mg, n=25 test  S
 ≥23 MPL vs
  ASA 81mg, n=25
NS = Nonsignifi cant result, S = Signifi cant result
Table 10. Results of antithrombotic interventional studies in patients with a history of 
recurrent miscarriage (RM), with or without thrombophilia
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Th ere are also other treatment options such as low-dose corticosteroids for 
patients with aPLs. However, in one study, such a treatment regimen did not 
improve pregnancy outcome and even increased the risk of preterm birth 
(Laskin et al 1997). Women with RM testing positive for severe aPS, have 
been shown to benefi t from intravenous immunoglobulin (IVIG) in some 
small series ( Kaaja et al 1993a, Vaquero et al 2001, Carp et al 2005) but no 
reduction in pregnancy loss was found in a larger analysis (Empson et al 
2005) or in an unselected RM population (Scott 2003).
Th e results of large randomized trials have been published showing 
no benefi cial eff ect of low-dose ASA in the prevention of recurrence of 
preeclampsia (Sibai et al 1993, Bar et al 1997, Caritis et al 1998), while there 
is a lack of data concerning the use of LMWH in this setting. Th ere are only 
a few (uncontrolled) studies on the treatment or prophylaxis of pregnancy 
complications such as preeclampsia or IUGR in thrombophilic patients 
(Riyazi et al. 1998, Kupferminc et al 2001). Recently, Sergio et al (2006) 
showed that LMWH plus ASA improves pregnancy outcome compared with 
ASA alone in patients with a history of severe preeclampsia. In the same 
setting, another study showed no diff erence in pregnancy outcome (Bar et 
al 2001). We have reported an extreme case of very early-onset preeclampsia 
in a women with FV mutation and reactio lutealis of the ovaries whose 
preeclampsia resolved aft er LMWH treatment and she delivered at term 
(Saisto et al 2004). In one study conducted among women with a previous 
history of preeclampsia without thrombophilic factors, and homozygous for 
the angiotensin-converting enzyme (ACE) D allele, LMWH administration 
reduced the recurrence of adverse clinical outcomes (Mello et al 2005a). In 
one study showed benefi cial eff ect of antithrombin concentrate in acute and 
severe preeclampsia (Maki et al 2000).
Th ere are also evidence that heparins may also have benefi cial eff ects other 
than anticoagulation, such as binding aPLs (Wagenknecht and McIntyre 
1992, Franklin and Kutteh 2003), an anti-infl ammatory eff ect (Manduteanu 
et al 2002, Rops et al 2004, Xia et al 2004) and complement inhibition 
(Girardi et al 2004). Pathogenetic mechanisms should be further elaborated, 
but if the role of thrombophilia turns out to be important we could have a 
good chance to improve pregnancy outcome in such patients through the 
use of LMWH. 
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7. Interaction between infl ammation and coagulation
Tissue factor, as a trigger of the coagulation cascade, is normally present in 
the circulation at low levels. Infl ammatory mediators such as endotoxin and 
infl ammatory cytokines (TNF-α, IL-1α) increase tissue factor expression 
in monocytes and macrophages, promoting coagulation. An increase of 
tissue factor expression caused by infl ammation shift s the hemostatic 
balance towards coagulation (Esmon 2003). In addition to its procoagulative 
eff ect, infl ammation also downregulates natural anticoagulants and inhibits 
fi brinolytic activity (Esmon 2003). Th e important natural anticoagulant 
pathway, the protein C pathway, is downregulated by infl ammation. 
Th rombomodulin and endothelial protein C receptor (EPCR) are inhibited 
by infl ammatory cytokines such as TNF-alpha (Conway and Rosenberg 
1988, Fukudome and Esmon 1994) (Fig. 4).
Fig. 4. Interaction between infl ammation and coagulation
 
 Endoth. cell P-selectin ↑
 Proinfl ammatory cytokines ↑
 Tissue factor ↑
 Platelet reactivity ↑
Infl ammation Fibrinogen ↑ Coagulation   Th rombin
 TM, EPCR ↓                                                         PAR 1–4
 Fibrinolysis ↓(PAI-1 ↑)
 APC ratio (↓    Preterm delivery
  
                        MMP            PROM
Th rombin has a key role in hemostatic mechanisms and in a variety of 
activities that result in augmentation of the infl ammatory response as well. 
Th rombin has the ability to regulate infl ammatory processes itself or via 
protease-activated receptors (PARs) (Dugina et al 2002, Esmon 2003). 
Activating PAR-1, thrombin induces intracellular adhesive molecule-1 
(ICAM-1) expression in endothelial cells. ICAM-1 has an important role 
in the development of the infl ammatory response through stimulation of 
leukocyte adhesion. Th rombin also induces expression of P- and E-selectins, 
vascular adhesive molecule-1 (VCAM-1), IL-8, IL-6 and chemokines (Dery et 
al 1998, Kaplanski et al 1998). Anticoagulatory factors such as antithrombin 
and protein C have regulatory and even protective capabilities as regards 
infl ammation (Bajzar et al 1996, Joyce et al 2001, Souter et al 2001). Several 
contractions
0.0 Alaotsikko 33
factors aff ecting infl ammation and coagulation have structural homologies, 
for instance tissue factor and cytokine receptors (Morrissey et al 1987).
Th ere is also evidence that thrombin has a uterotonic eff ect (Elovitz et al 
2000, O’Sullivan et al 2004). Th rombin also enhances the expression of 
decidual matrix metalloproteinases (MMPs), this being strongly linked 
to premature rupture of the membranes (Rosen et al 2002, Stephenson 
et al 2005). Premature rupture of the membranes and premature delivery 
are associated with excess generation of thrombin (Rosen et al 2001, 
Chaiworapongsa et al 2002).
7.1 Preterm delivery
Th e causes of prematurity are multifactorial but uterine infection plays an 
important role in the etiology of premature delivery (Slattery and Morrison 
2002). Any systemic maternal infection during the preterm period can trigger 
the onset of preterm delivery (Slattery and Morrison 2002). Even periodontal 
infection has been suggested to be a source of cytokines, increasing the risk 
of preterm delivery (Off enbacher et al 1996, Boggess et al 2005). However, 
infections are most oft en subclinical, without any signs of maternal infection. 
Genital tract infections such as bacterial vaginosis (BV) are associated 
with an increased risk of preterm delivery (Hay et al 1994, Goldenberg 
et al 2000). Furthermore, either ascending microbial colonization from 
the vagina to the uterus, or colonization via the hematogenic route, both 
causing endotoxin and exotoxin production and activation of infl ammatory 
cytokines (IL-1, IL-8, IL-6 and TNFα) (Lockwood and Kuczynski 1999), 
leads to induction of prostaglandin synthesis, an increase in the activity of 
various proteases, contraction and fi nally preterm rupture of the membranes 
(PROM) (Goldenberg et al 2000).
Although an association between BV and preterm delivery has been 
shown, the benefi t of antibiotic treatment has remained minor (Brocklehurst 
et al 2000, Kekki et al 2001). A benefi cial eff ect of prophylactic antibiotic 
treatment has been shown in cases of PROM (Kenyon et al 2001). Despite 
intensive research, there are still many open questions connected with the 
pathophysiology and prevention of preterm delivery. 
7.2 Cervical insuffi ciency
Cervical insuffi  ciency is defi ned as inability of the uterine cervix to retain 
pregnancy in the absence of contractions or labor. It is clinically characterized 
by acute, painless dilatation of the cervix, usually in the second trimester, 
culminating in protrusion and/or premature rupture of the membranes, 
and premature delivery. Th e condition was clinically described in the 
1950s (Shirodkar 1955) but its etiology has remained unclear. Reported 
incidences of cervical insuffi  ciency are low, with estimations varying from 
1:1800 to 1:182 (Barter et al 1958, Harger 1980, Lidegaard 1994). Th e great 
variability of incidences in diff erent studies is perhaps the result of diff erent 
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diagnostic criteria. It has been suspected that various cervical traumas, 
pregnancy terminations or obstetric lacerations, as well as congenital uterine 
abnormalities might be risk factors of cervical insuffi  ciency, but evidence is 
still limited (American College of Obstetricians and Gynecologists 2003). 
Despite the known risk factors, predicting premature delivery has been 
very diffi  cult. Th e main treatment options have been either bed rest or 
cervical cerclage, the eff ectiveness of which has not been proven (To et al 
2004). Cervical insuffi  ciency can be involved in one form of prematurity, 
in which uterine infection with activation of infl ammatory cytokines (IL-1, 
IL-8 and TNFα) plays an important role (Lockwood and Kuczynski 1999). 
Interactions between infl ammation and thrombosis (Esmon 2003) give us 
a new viewpoint in regard to premature delivery. 
8. Genetic polymorphism of coagulation factors in 
recurrent miscarriage
Th ere are several studies concerning genetic polymorphism in RM. Th e 
most common thrombophilias associated with fetal losses are listed in 
table 8 . Th ere are also numerous studies concerning identifi cation of 
polymorphism of coagulation factors (e.g. TF, TFPI, fi brinogen, FXII, FXIII), 
the clinical relevance of which, even in pregnancy complications, has not 
been ascertained (Bertina 2001). 
8.1 Plasminogen activator inhibitor I (PAI-1) and Coagulation 
factor XIII
For successful implantation, plasminogen activator inhibitor type 1 (PAI-1) 
is believed to control maternal tissue during trophoblast invasion. In the 
coagulation mechanism, coagulation factor XIII fi nally cross-links fi brin. 
Homozygosity of PAI-1 4G, and FXIII34 Leu polymorphism have also 
been associated with RM (Dossenbach-Glaninger et al 2003). Impaired 
fi brinolysis may result in insuffi  cient trophoblast invasion and unbalanced 
fi brin deposition.
8.2 Thrombomodulin and Endothelial protein C receptor 
polymorphism
Animal models are one possibility to fi nd out whether genes are essential or 
not for normal embryonic development. Th ese include two thrombophilia-
associated genes, those for thrombomodulin (TM) and for endothelial protein 
C receptor (EPCR), suspected to be associated with RM. Loss of function of 
TM causes early post-implantation embryonic lethality before establishment 
of a functional cardiovascular system in the mouse embryo (Healy et al 
1995). Embryogenesis is disrupted at two diff erent developmental stages, 
indicating a crucial role for TM in both. Expression of TM in non-endothelial 
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placental cells is required for proper function of the early placenta, while the 
absence of TM from blood vessel endothelium causes excessive activation 
of the embryonic blood coagulation system (Isermann et al 2001).
Deletion of the EPCR gene in mice leads to embryonic lethality before 
embryonic day 10.5. However, EPCR /  embryos removed from extra-
embryonic membranes and tissues at day E7.5 and cultured in vitro 
developed beyond E10.5, suggesting a role for EPCR in the normal function 
of the placenta and/or at the maternal-embryonic interface (Gu et al 2002). 
Endothelial protein C receptor is normally detected on giant trophoblast 
cells, which are in direct contact with the maternal circulation and its 
clotting factors. If EPCR is not expressed on the giant trophoblast cells, 
even enhanced expression of EPCR in the embryo cannot rescue the embryo. 
Conversely, selective EPCR expression on the giant trophoblast cells rescues 
EPCR-defi cient embryos (Li et al 2005). Th rombosis is observed surrounding 
trophoblast giant cells derived from EPCR /  embryos but not around those 
derived from EPCR+/+ or EPCR+/  cells (Gu et al 2002). Th ese observations 
suggest that extra-embryonic EPCR expression is essential for embryonic 
viability and plays a critical role in the control of blood coagulation at the 
feto-maternal interface.
Th rombomodulin and EPCR are glycoprotein receptors that both play 
key roles in the protein C anticoagulant pathway, the major regulatory 
mechanism that suppresses coagulation. Th rombomodulin is an endothelial 
cell surface receptor expressed mainly on the endothelial surfaces of blood 
vessels and in the placenta. It forms a complex with thrombin, which then 
converts protein C to activated protein C (Maruyama et al 1985, Van de 
Wouwer et al 2004, Dahlbäck and Villoutreix 2005). Endothelial protein 
C receptor is a type 1 transmembrane receptor, expressed primarily on 
endothelial cells of large blood vessels and in the placenta and developing 
cardiovascular system in the fetus. It functions in the protein C pathway by 
binding protein C and presenting it to the TM-thrombin complex on the 
endothelium, thereby increasing the rate of protein C activation (Stearns-
Kurosawa et al 1996, Laszik et al 1997, Crawley et al 2002).
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9. Aims of the study
Th e aims of the study were to investigate
I. the impact of initial treatment of DVT during pregnancy with 
LMWH compared with the traditional treatment with UFH on pregnancy 
and maternal long-term outcome
II. the potential role of hereditary thrombophilias in the 
pathophysiology of cervical insuffi  ciency by studying the prevalence of 
hereditary thrombophilias in cervical insuffi  ciency 
III. plasma levels of annexins IV and V at the beginning of pregnancy in 
women with a history of recurrent miscarriage, and the association of these 
annexin plasma levels with the presence of antiphospholipid antibodies 
IV. polymorphism of TM and EPCR in women with a history of RM
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10. Material and Methods
Altogether, 153 patients and 818 controls were investigated in connection 
with this thesis. A description of the studies (I–V) is presented in table 11. 
Th e study protocols were approved by the local ethics committee.
Table 11. Patients and methods in Studies I–V. 
 Study I Study II Study III Study IV Study V
Study group patients with DVT patients with post-DVT patients with patients with  patients with
 during pregnancy during pregnancy cervical insuffi  ciency RM RM
Design prospective, prospective, retrospective prospective retrospective
 observational observational case-control comparative case-control
 LMWH vs UFH LMWH vs UFH 
Outcome Maternal outcome  prevalence of PTS prevalence of  levels of annexin IV prevalence of
 of DVT aft er DVT FV and prothrombin and V associated TM and EPCR
   mutation with the presence polymorphism
    of aPL
Number of patients 21 LMWH 25 LMWH 42 68 patients 86
  21 from study I  77 pregnancies 
    25 controls
Controls 10 UFH 10 UFH 617 healthy 25 191, no history
   blood donors  of miscarriage
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General hemostatic tests used in studies I–V
In patients using UFH, APTT was measured with ACL Futura and ACL 
2000 equipment (Instrumentarium Laboratory, Helsinki, Finland) and the 
reagent PTT AUTOMATE (Diagnostica Stago, Paris, France). 
Anti-Xa measurements (patients with LMWH) were carried out by using 
a chromogenic substrate assay based on inhibition of bovine factor Xa 
by heparin-activated antithrombin III (HEPRN method, DuPont aca IN 
analyser, DuPont Co., Wilmington, DE, USA). APTT (normal range 24–34 
sec) was measured by using Platelin LS equipment (Organon Teknika, Boxtel, 
the Netherlands).
All patients in studies I–V were analyzed for hereditary and acquired 
thrombophilia. Factor V Leiden was analyzed by the method described by 
Bertina et al (1994), and the G20210A prothrombin mutation by the method 
described by Poort et al (1996). Lupus anticoagulant was studied by using the 
Russell Viper Venom Test, with pooled normal plasma in confi rmatory tests, 
anti-cardiolipin IgG (normal if <10 GPL) by QUACA Anti-Cardiolipin Elisa 
(Cheshire Diagnostics Limited, Great Britain), anti-thrombin by Coamatic 
AT 400 (normal range 84–108% of normal control) (Chromogenix AB, 
Mölndal, Sweden), protein C (normal range 67–131% of normal control) 
by Coamatic Protein C (Chromogenix AB, Mölndal, Sweden), APC ratio 
(normal if >2) by using kits from Chromogenix AB (Mölndal, Sweden), and 
protein S (normal range 43–126% of normal control) by Liatest Protein S 
(Diagnostica Stago, Asnieres, France). 
Study I
Th e fi rst 10 consecutive patients received intravenous unfractionated heparin 
for treatment of acute DVT, and the next 21 patients received low molecular 
weight heparin (dalteparin). Most patients (29) had DVT in the lower limbs, 
but two had it in the upper limbs. In all cases, diagnosis was based on 
compression ultrasonography (CUS, color Doppler). Ultrasonographic 
examination was repeated 2–6 weeks aft er starting heparin treatment if 
symptoms occurred or there was suspicion of recurrence in the aff ected limb. 
Treatment length was 7 days in both groups. In the UFH group a bolus of 
5000 IU was injected and thereaft er the daily dose was 15 000 IU/500 ml 
infused at 36 ml/h. Treatment was followed by means of repeated plasma 
APTT measurements (every six hours) and the target value was 50–100 
seconds. Th e next 21 patients were treated subcutaneously with dalteparin, 
200 IU/kg/d, divided into two doses. Th e doses were adjusted by means of 
anti-Xa measurements; target levels 0.5 and 1.5 IU/ml (before and 3 hours 
aft er subcutaneous injection, respectively). 
Both groups received either dalteparin (28) or the LMWH enoxaparin 
(1) for secondary prophylaxis at treatment doses during the following two 
weeks and thereaft er the dose (twice a day) was gradually decreased until 
delivery. Th is prophylactic LMWH dose at the end of pregnancy was adjusted 
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on the basis of plasma anti-Xa measurements (target 3 hours aft er injection: 
0.5–0.7 IU/ml). 
Th e LMWH doses were halved on the day of delivery in both groups. 
Aft er delivery the patients were treated with warfarin (3–6 months) and 
LMWH was stopped when INR was 2–3 for at least two days.
Effi  cacy of treatment was evaluated daily by measuring the circumference 
of the aff ected limb at the mid-femoral and crural level and by investigating the 
occurrence of post-thrombotic symptoms (pain, edema, physical limitations 
and paresthesia). Re-examination by means of US was performed in cases 
of worsening of the post-thrombotic symptoms 2–6 weeks aft er starting 
treatment. Pulmonary ventilation scans were performed only in cases of 
clinical suspicion of PE. Platelet levels were followed during both acute 
treatment and prophylaxis. Episodes of bleeding (hematomas, hematuria, 
gingival and vaginal bleeding) were recorded.
Study II
Our patients were recruited from a previous open prospective observational 
study in which LMWH and UFH were compared in the initial treatment 
of DVT during pregnancy (Ulander et al 2002). Th irty-fi ve patients with 
DVT in the lower limbs were enrolled in the study. Ten consecutive patients 
received iv UFH for treatment of acute DVT, then the next 25 patients 
(4 patients additional to those in Study I) received LMWH for the same 
indication. Th e diagnosis was based on compression ultrasonographic (color 
Doppler) examinations.
To evaluate the prevalence of post-thrombotic symptoms, we used a 
modifi cation of a protocol described by Villalta et al (1994). In this protocol, 
the presence of symptoms (feelings of heaviness, pain, cramps, pruritus and 
paresthesia) and signs (edema, redness, pain during calf compression, skin 
hyperpigmentation, new venous ectasia) of PTS was noted. For each item 
a score of 0 (= no or minimal) to 3 (= severe) was assigned. A score of ≥ 15 
indicates severe PTS and a score of 5–14 indicates mild or moderate PTS 
(appendix II).
Duplex Doppler ultrasonographic examination was carried out among 17 
patients. Eighteen patients did not want to participate in the US examination, 
mostly because they were symptomless. Ultrasonography was performed 
by a single experienced vascular surgeon (A.L). Th e examination was 
carried out with color-duplex equipment (Image Point®/Hewlett Packard) 
using Sonos 5500 in both supine and upright positions. Refl ux (> 0.5 sec) 
was determined in a non-weight-bearing leg in an upright position with 
the aid of a mechanical distal muscle pump and Veno-Pulse® equipment 
(Stranden). Th e examination included scanning of the external iliac, deep 
and superfi cial femoral, popliteal and calf veins as well as superfi cial veins. 
Valvular incompetence was defi ned by the presence or absence of refl ux aft er 
distal compression. Th e fi ndings were categorized using the international 
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CEAP (C = Clinical, E = Etiology, A = Anatomy, P = Pathophysiology) 
classifi cation (Porter and Moneta 1995) (appendix III).
Study III
Fift y-eight consecutive patients with a diagnosis of cervical insuffi  ciency 
(ICD-10: O34.3) treated in Helsinki University Hospital from 1996 to 2003 
were fi rst identifi ed. Th e diagnosis was confi rmed from the hospital records. 
Cases of intrauterine fetal death were excluded, as were twin pregnancies 
and patients with congenital uterine anomalies. Of the 58 patients, 42 were 
willing to participate in the study and gave informed consent.
At admission of the patients to the hospital, abnormal cervical culture 
results, and clinical infection defi ned by elevated levels of serum C-reactive 
protein (CRP), or clinical signs of infection were recorded. A possible history 
of sexually transmitted disease was recorded from hospital fi les and acute 
infection was excluded by means of cervical cultures or specifi c PCR tests.
Th e control group consisted of 617 healthy Finnish blood donors recruited 
as fi rst-time donors by the Finnish Red Cross Blood Service. Th is group 
included both sexes, as FV Leiden mutation and prothrombin gene G20210A 
mutation are not linked to gender.
Th e prevalence of common hereditary thrombophilic mutations (FV 
Leiden, prothrombin) were examined among patients with a history of 
cervical insuffi  ciency compared healthy control population.
Study IV
Sixty-eight women with recurrent miscarriage were included in the study. 
At the time of recruitment, all subjects had positive pregnancy test results 
before 6 weeks of gestation, which was judged by the last menstrual period. 
All women conceived spontaneously. Th e women were examined for the 
presence of known etiological factors of RM. Hereditary thrombophilia 
tests were performed as described above. Patients were followed at out-
patient clinic and blood samples were collected in the fi rst visit (5th weeks 
of gestation), 6th and 8th weeks of gestation. Patients aPL status was carefully 
examined. Annexin IV and V levels were investigated in those visits and 
compared with the presence of aPL. Moreover, 25 unselected controls without 
a history of adverse pregnancy outcome were included in the study. Th ese 
women volunteered to have their annexin levels assessed at the 6th and 8th 
weeks of gestation.
1. Acquired thrombophilias, defi ned by the presence of lupus anticoagulant, 
were assessed by dRVTT and PTT-LA tests. Anticardiolipin antibodies 
were assayed as described previously in detail (Vaarala et al 1993). 
Concentrations of IgM aCL antibodies were determined in the same way 
as for IgG aCL antibodies except that alkaline phosphatase-conjugated 
anti-human IgM was used as the detector antibody. Th e cut-off  level for 
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positivity was determined as a result exceeding 10 IgG phospholipid (GPL) 
antibody units for IgG class aCL antibodies, and 20 IgM phospholipid 
antibodies (MPL) for IgM class aCL antibodies. 
2. Antiphosphatidylserine antibodies of IgG class were measured in 
the same way as aCL antibodies. Microtiter wells were coated with 
phosphatidylserine (P-6641 / P-8518, Sigma Aldrich, St. Louis, MO), 
diluted 1:200 in chloroform-methanol (1:3). Th e wells were left  to dry 
overnight at 4 oC and post-coated with 10% bovine serum in PBS; 
thereaft er the assay was continued as in aCL determinations. Th e cut-off  
level for positivity was set at mean + 2 SD (0.184 OD units) of samples 
from 100 blood donors. 
3. A detailed description of the antiprothrombin antibodies has been 
published previously (Puurunen et al 1996). Th e cut-off  limit for positivity 
was set at the 95th percentile of samples from 200 normal blood donors 
(0.379 OD units).
4. Th e assay for anti-β2 glycoprotein I (anti-β2GPI) was performed in the 
similar manner as the ELISA for antiprothrombinwith the exceptions 
that the concentration of anti-β2GPI used for coating was 5 µg/ml and 
the samples were diluted at 1:200. Th e mean + 3 SD of samples from 98 
blood donors (0.143 OD units) was used as the cut-off  limit for positivity. 
All subjects with abnormal values were re-evaluated two months later. 
5. Blood samples for assay of annexins IV and V were collected using tubes 
containing EDTA at the time of recruitment, and at 6 and 8 weeks of 
gestation. In cases of miscarriage, further blood samples were not taken. 
Platelet-poor plasma (PPP) was separated by centrifugation twice at 2,540 
g for 15 min and stored at -70 °C until assayed. Concentrations of annexin 
IV in plasma were determined by sandwich ELISA using PAB-AX4 to 
human Anx IV for capture and biotin-conjugated AS17 for detection. 
Th e standard curve was obtained using His-rAnx IV. Concentrations 
of annexin V in plasma were determined by using a human annexin V 
ELISA kit (Bender MedSystems Products, Vienna, Austria), as previously 
described.(Masuda et al 2004).
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Study V
Polymerase chain reaction 
DNA was extracted from whole blood collected from patients with RM (n=40 
couples and 6 women) and controls (n=191) using Puregene DNA isolation 
kits (Gentra Systems, Minneapolis, USA). Polymerase chain reactions of 
TM and EPCR exons (non-coding exons included) were performed in a 25 
µl reaction mix containing the following reagents: 50–100 ng of genomic 
DNA, 1× PCR buff er (Applied Biosystems, Foster City, USA), 2 nmol of each 
dNTP, 10 pmol forward primer, 10 pmol reverse primer and 0.1 units of 
AmpliTaq Gold DNA-polymerase (Applied Biosystems, Foster City, USA). 
Additionally, DMSO (fi nal concentration 5% (v/v)) was added to some of 
the amplicons. Th ermocycling was performed in a PTC-225 DNA Engine 
Tetrad thermocycler (MJ Research, Waltham, USA). Initial denaturation at 
95 °C for 10 min was followed by 35 cycles of denaturation at 95 °C for 30s, 
annealing for 45 s (temperature depending on the amplicon), and extension 
at 72 °C for 45 s. Final extension was performed at 72 °C for 10 min. PCR 
conditions and primer sequences are shown in Table 12. Th e specifi city 
of the amplifi cation was confi rmed by agarose gel electrophoresis before 
further analysis.
Mutation analysis
Denaturing high performance liquid chromatography (DHPLC) analysis 
of the samples was carried out using a Transgenomic WAVE® Nucleic Acid 
Fragment Analysis System (Transgenomic, Omaha, USA) and the associated 
Navigator soft ware as described by Kaare et al (2006). Conditions used 
for DHPLC analysis are shown in Table 12. Following DHPLC screening, 
samples showing heterozygous peaks were sequenced in order to determine 
the nature of the sequence change. Additionally, for each amplicon, 10 
samples showing only a homoduplex peak were sequenced to confi rm that 
no variation went undetected. Direct sequencing was performed using 
BigDye version 3.1 sequencing chemistry and an ABI 3730 DNA Analyzer 
(Applied Biosystems, Foster City, USA). 
By means of sequencing, a c.1418C>T variation in TM was detected. 
Th is variation was not detected by DHPLC. All samples were genotyped 
using the restriction enzyme Cac8I (New England Biolabs, Ipswich, USA). 
Homozygosity for EPCR variations c.655A>G and c.717+16G>C were also 
detected by RFLP using restriction enzymes AciI and DdeI, respectively. Aft er 
digestion the restriction pattern was visualized in agarose gel. Homozygosity 
of EPCR variation c.323-20T>C was genotyped using DHPLC. To detect 
homozygous variations, 5 µl of the genotyped samples were mixed with 
5 µl of a reference sample with no variations, and analyzed on the WAVE 
System. Homozygosity of TM variation c.1728+23_+40del, and EPCR c.323-
9_336dup were genotyped using 3% agarose gels, on which an 18/23 bp 
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diff erence in fragment sizes was detected.Th e nature of variations predicted 
to change an amino acid were analyzed by the SIFT (Sorting Intolerant From 
Tolerant) program (http://blocks.fh crc.org/sift /SIFT.html).
Statistical analysis 
Continuous variables were presented as means (+/- SD) ana were analysed 
by using Student´s t-test. In the cases of skewness of data, non-parametric 
Mann-Whitney test was used to analyse dieff erences between studygroups 
(studies I, II, IV, V). Logistic regression analysis was used in study II to 
identifi ed risk factors of PTS. In study III was used X 2 –test to analyse 
categorical data. Kruskal-Wallis ANOVA with multiple-comparison Z-Value 
Test were used to analyse diff erences between annexin levels in study IV. 
Th e statistical analyses were performed by means of NCSS soft ware version 




11.1 Outcome of deep venous thrombosis (I, II)
Th ere were no statistically signifi cant diff erences in baseline maternal or 
neonatal data between the groups. On the basis of our results, LMWH was 
as eff ective and safe as unfractionated heparin in the treatment of DVT 
during pregnancy. Th e gestational age of DVT tended to be lower in the 
LMWH group (21 weeks of gestation) than in the UFH group (27 weeks of 
gestation), but the diff erence did not reach statistical signifi cance. Th e time 
from the beginning of symptoms to diagnosis (diagnostic delay) tended to 
be relatively long in both treatment groups (8 days in the UFH group and 
7 days in the LMWH group; table 12). 
In 23 (74.2%) of the cases DVT was in the left  leg and in 24 (77.4%) cases 
it was in the proximal region of the lower limb. Th ere were no statistically 
signifi cant diff erences in thrombophilic data or localization of the DVT 
between the groups. 
Table 12. Th rombophilic data and localization of deep venous thrombosis (DVT) 
during pregnancy 
 UFH (n=10) LMWH (n=21) p
Weeks of gestation at diagnosis, mean (SD) 27.0 (8.5) 21.0 (9.8) NS
Personal history of DVT, n (%) 1 (10) 4 (19.0) NS
Family history of DVT, n (%) 3 (33.3) 9 (42.9) NS
Hereditary thrombophilia, n (%) 2 (20) 7 (33.3) NS
Acquired thrombophilia, n (%) 0 (0) 1 (4.8) NS
Localization of DVT, n (%)
Lower limb, proximal 8 (80) 16 (76.2) NS
Lower limb, distal  2 (20) 3 (14.3) NS
Upper limb 0 (0) 2 (9.5) NS
Lower left /lower right limb*  8/2  15/4 NS
Delay in diagnosis, days**  7.9 (9.3) 6.8 (8.1) NS
Failures of treatment, n  0 1 (recurrent DVT) NS
Dose for LMWH prophylaxis, IU/24 h   7777 (1954) 7875 (2470) NS
Mean (SD) 
Symptoms aft er treatment, n (%) 4 (40)   8 (38) NS
Re-canalized thrombi in US, n 1/6  7/11 NS
Hemorrhagic complications during treatment 0 0 NS
*(left  vs. right side in all patients, p<0.05), NS=not signifi cant
**Time from onset of symptoms to diagnosis and treatment
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No PE was detected. One failure of treatment was found in a patient who 
had proximal DVT. Aft er the acute period of DVT treatment, both groups 
received equivalent doses of LMWH for thromboprophylaxis. Th ere were no 
diff erences in symptoms (pain or edema) in the aff ected limb aft er treatment. 
In 17 patients (54.8%) re-examination of the veins by ultrasonography 
was performed 4 weeks aft er treatment and re-canalization was evident in 
16.7% and 63.6% of patients in the UFH and LMWH groups respectively, 
but the diff erence was not statistically signifi cant (p=0.06, Fisher´s exact 
probability test). 
Th ere were no congenital anomalies or treatment-associated side eff ects 
(osteoporosis, thrombocytopenia) during pregnancy. One patient in the 
LMWH group had hematuria, but this occurred during the prophylactic 
phase. It disappeared spontaneously aft er decreasing the dose of LMWH. 
One infant died aft er premature delivery at 23 gestational weeks (birth weight 
of 340 g) as a result of severe preeclampsia. Th e mother had a positive lupus 
anticoagulant test result and DVT nine weeks before premature delivery. 
Epidural anesthesia was given if the dose of LMWH was low/moderate (5000 
IU for dalteparin) and given 12 hours before delivery. Epidural anesthesia 
could be given in 35% of our patients. Th e decision on mode of delivery was 
made on the basis of obstetric factors in both groups. Delivery and neonatal 
data did not diff er between the groups and were the same as observed in 
healthy women at our unit.
Th ere were no diff erences in long-term outcome aft er pregnancy-
associated DVT, initially treated with either LMWH or UFH. Long-term 
outcome was evaluated by means of a questionnaire and by duplex Doppler 
US examination.
Th e mean doses of heparin for the initial phase of treatment were 25 
537 IU/24 hours in the UFH group and 16 000 IU/24 hours in the LMWH 
group during a one-week period. Both groups received equal doses of 
LMWH (mean 7500 IU/24 hours) for secondary prophylaxis until the end 
of pregnancy. 
Th ere were no signifi cant diff erences in demographic data between the 
treatment groups. In 20 cases (57%) DVT was proximal (femoral, iliac). 
One patient delivered aft er the fi rst episode of DVT and one patient had 
recurrent DVT aft er the index pregnancy. 
Post-thrombotic syndrome scoring was performed according to Villalta 
et al (1994). Th e analysis was carried out at a mean of 51 ± 26 (SD) months 
aft er thrombosis in the UFH group and aft er 42 ± 17 months in the LMWH 
group (NS). Th e mean post-thrombotic score was 5.8 in the UFH group 
and 4.7 in the LMWH group (NS). Forty-nine percent of all patients had a 
score of four or less (no signs or symptoms of post-thrombotic syndrome). 
No patient had ulcers.
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Table 13. Long-term outcome of DVT
 UFH (n=10) LMWH (n=25) p
Age, mean (SD)  31.6 (5.1) 32.6 (5.3)  NS
BMI, mean (SD)  23.3 (4.0) 25.2 (4.5) NS
Multiple DVT 1 1) 9 2)
Localization (%)
Distal 4 (40) 11 (44)  NS 
Proximal 6 (60) 14 (56)  NS
Th rombophilia-positive 3) (%) 2 (20) 6 (24) NS
Post-thrombotic symptoms (n=35)
Time since DVT (years), mean (SD) 4.3 (2.2) 3.6 (1.4)  NS
Villalta score, mean (SD) 5.8 (4.1) 4.7 (3.5) NS
Villalta score ≤ 4 (%) 4 (40) 13 (52) NS
(no PTS symptoms)
Villalta score 5–14 (%) 6 (60) 12 (48) NS
(mild or moderate PTS symptoms)
Duplex Doppler US (n=17)
Not performed 5 5
Normal 1 5
Superfi cial venous insuffi  ciency or 1 6
refl ux 
Deep venous insuffi  ciency or 1 2
refl ux
Operated varicose veins 2 2
1) Recurrent DVT aft er index pregnancy
2) All before index pregnancy
3) Two patients positive for lupus anticoagulant, one patient with high anticardiolipin antibodies 
(IgG), six patients with FV Leiden mutation (heterozygote) and one patient with a constantly high 
level of FVIII (> 150 IU)
Seventeen patients were examined by means of duplex Doppler ultrasonography. 
Seven patients (1 in the UFH group and 6 in the LMWH group, NS) had 
superfi cial venous insuffi  ciency and three patients (1 in the UFH group and 2 
in the LMWH group, NS) had deep venous insuffi  ciency. One patient without 
leg ulceration had severe PTS as defi ned by symptoms and ultrasonography. 
Four patients had been operated on for varicose veins.
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Table14. Prevalence of post-thrombotic symptoms according to localization of DVT
Localization of DVT No symptoms Mild or moderate PTS  severe PTS
 (Villalta score ≤ 4) (Villalta score 5–14 or (Villalta score ≥ 15 
  superfi c. ven. insuff.)  or deep ven. insuff. 
Distal DVT 5/15 (33.3%) 8/15 (53.3%) 2/15 (13.3%)
Proximal DVT 13/20 (65%) 6/20 (30%) 1/20 (5%)
Th e total incidence of post-thrombotic symptoms was 51%. In multivariate 
logistic regression analysis no prognostic factors were found as regards 
severe post-thrombotic symptoms (Villalta score ≥ 15 or deep venous 
insuffi  ciency).
11.2 Prevalence of FV Leiden and prothrombin G20210A 
mutation in cervical insuffi ciency
Th rombophilic mutation was found signifi cantly more oft en among women 
with a history of cervical insuffi  ciency compared with controls (OR 6.7, 95% 
CI 2.7–18.4; table 15). Th e prevalence of cervical insuffi  ciency was 2 per 
1000 deliveries in our hospital. Th e mean age of the study population was 
36 years (range 25–46 years) and the mean body mass index (BMI) during 
the last pregnancy was 22 kg/m2 (range 18–35 kg/m2). Nine patients with 
past Chlamydia trachomatis infection were found. 
Forty-two patients had had 122 pregnancies. Of the thrombophilic 
patients, 1/7 (14%) had had a history of dilatation and curettage as a result 
of legal pregnancy termination and another one (14%) had had cervical 
laceration. Th e prevalence of cervical procedures or traumas was greater in 
non-thrombophilic patients (74%) than in thrombophilic patients (28%).
Table 15 . Th rombophilic mutations (FV and FII) in patients with a history of 
cervical insuffi  ciency (n=42), and general population (n=617)
 Patients, n (%)  Controls, n (%) OR (95% CI)
FV Leiden  4 (9.5) 15 (2.4) 4.2 (1.5–13.6)
Prothrombin  3 (7.1) 3 (0.5) 15.7 (3.4–70.9)
G20210A 
FV Leiden or  7 (16.7) 18 (2.9) 6.7 (2.7–18.4)
Prothrombin G20210A
Th e patients were also tested for other hereditary thrombophilias and one 
patient with repeatedly low protein C activity but a normal antigen level 
was found. None of the patients had antithrombin or protein S defi ciency. 
Th ese fi ndings were not included in the statistical analysis and not analyzed 
in the controls.
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11.3 Annexin IV and V levels in early pregnancy in patients with 
a history of RM
Sixty-eight women with a history of RM participated in the study. Th ere was 
a total of 77 pregnancies in the study group. Th e demographic data between 
studygroups (aPL positive vs aPL negative) did not diff er. Seventy-three 
percent of the subjects were primary aborters without successful pregnancies. 
Hereditary or acquired thrombophilic disorders were found in 53% (36/68) 
of the subjects. Table 16.







Primary aborters 16 33
Secondary aborters 10 9
Number of miscarriages
 3 fi rst trimester 19 23
 4 fi rst trimester 3 10
 5 fi rst trimester 2 0
 on second trimester (>22 th) 5 7
Controls  25
miscarriages  3
Plasma levels of annexin V were signifi cantly higher at the beginning 
of pregnancy in women with aPL antibodies (lupus anticoagulant, aCL, 
antiphosphatidylserine, antiprothrombin, and/or anti-β2-GPI) compared 
with those without aPL antibodies (p=0.03). Levels of circulating annexin 
V were also higher at the 6th patients among aPL antibodies (P= 0.01) than 
aPL negative patients and controls. At 8th weeks of gestation in subjects with 
aPL antibodies annexin V levels were also higher than aPL negative patients 
(P=0.01) but the diff erence between aPL positive and controls did not reach 
statistical signifi cance 
Plasma levels of annexin V were also studied in relation to pregnancy 
outcome. A tendency towards higher plasma levels of annexin V was 
observed in those whose pregnancies ended in miscarriage compared with 
those with successful pregnancy, although the results did not reach statistical 
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signifi cance (p=0.10). Th e plasma levels of annexin V were also analyzed 
in relation to the presence of anti-β2GPI antibodies, but no statistically 
signifi cant diff erence was found.
Plasma levels of annexin IV at the fi rst visit in women with aPL antibodies 
were similar to those at 6 and 8 weeks of gestation. Moreover, there were no 
signifi cant diff erences in plasma annexin IV levels between women with and 
without aPL antibodies. Th e plasma level of annexin IV was not of prognostic 
value as regards pregnancy outcome.
11.4 Prevalence of TM and EPCR polymorphism in recurrent 
miscarriage (RM)
In total, 86 cases (40 couples and 6 women) with a history of unexplained 
RM and 191 controls were screened by means of DHPLC for mutations in 
TM and EPCR genes. Two sequence variations in the TM gene and four in 
the EPCR gene were found (table 17). We did not fi nd signifi cant diff erences 
in the prevalence of TM and EPCR polymorphism among couples suff ering 
from RM compared with controls.
All variations were detected in both patients and controls. Th ere were 
no signifi cant diff erences in the allele or genotype frequencies between 
patients and controls for any of the sequence variations. Th e 40 couples 
included in this study were also analyzed to determine if the variations 
existed in both partners. Th e common variations c.323-20T>C, c.655A>G, 
and c.717+16G>C in the EPCR gene and c.1418C>T in the TM gene were 
all detected in both partners of a couple, enabling a homozygous state in the 
fetus. Additionally, the newly identifi ed 1728+23_+40 deletion was detected 
in a heterozygous state in both partners of one couple.
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Table 17. TM and EPCR sequence variations. Locations of the variations, predicted 
amino acid changes, and the numbers of patients and controls carrying the rarer 
allele in a hetero/homozygous state. Numbering of the nucleotides is relative to the 
adenine in the ATG start codon in the reference sequence.
  Heterozygous patients Hetero-
zygous controls 
DNA variation  (homozygous patients) (ho-
mozygous controls)
(predicted amino acid change) Location n=86 n=191
TM variations   
c.1418C>T (Ala455Val) exon 1 41 (5) 84 (8)
c.1728+23_+40del1 3´UTR 5 5
   
EPCR variations   
c.323-20T>C  intron 2  41 (15) 95 (33)
c.323-9_336dup 
(TyrProGlnPheLeuSTOP) exon 3  2 1
c.655A>G (Ser219Gly) exon 4 22 (1) 49 (2)
c.717+16G>C  3´UTR  41 (15) 93 (34)
1 Novel variation (not previously reported)
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12. Discussion
12.1 Venous thromboembolism 
Th e established treatment for DVT during pregnancy before this study was 
administration of unfractionated intravenous heparin (Greer and De Swiet 
1993, Lowe 1997). It is still widely used in many countries (e.g. the US). Th ere 
is a lack of randomized studies on the treatment of DVT during pregnancy 
in regard to comparison of LMWH with unfractionated heparin. At present, 
doses of LMWH in the treatment of DVT during pregnancy have been settled 
(1 mg/kg or 100 IU/kg twice daily) for the initial treatment, but the duration 
of the treatment phase and the doses during the rest of the pregnancy are 
not yet fi xed. Recommendations for duration of the treatment phase and 
the doses of LMWH towards the end of pregnancy are based only on the 
results of small observational studies, and expert recommendations (Bates 
et al 2004, Greer and Hunt 2005). In our study the starting doses for DVT 
treatment were slightly higher than recommended by the manufacturer, with 
a mean daily dalteparin dose of 16 000 IU per mean body weight of 70 kg. 
Aft er the initial treatment phase all patients were given treatment doses of 
LMWH for another two weeks. Th ereaft er the dose was gradually decreased 
to a high prophylactic level depending on the anti-Xa results. In our study 
one recurrence of DVT was observed in the early secondary prophylactic 
phase and thus we recommend extension of the treatment phase to at least 
4–6 weeks, continuing with doses near the treatment dose (80%; twice a day) 
until delivery. Nowadays, there are two main alternatives for treatment: 1) the 
dose is adjusted according to total body weight and continued to the end of 
pregnancy, because pregnancy itself is a hypercoagulable state and the risk 
of recurrence is higher towards the end of pregnancy, and 2) aft er the acute 
phase of treatment the dose of LMWH is reduced because of concerns that 
therapeutic doses of LMWH may carry a risk of osteoporosis and bleeding 
(Greer and Hunt 2005). Our clinical practise follows the fi rst alternative. 
Anti-FXa-based dose adjustments could be made in the steady-state phase of 
treatment of VTE. Low molecular weight heparin does not cross the placenta; 
thus fetoplacental weight is not relevant (Greer and Hunt 2005). Moreover, 
adipose tissue receives a comparatively small blood supply (Greer and Hunt 
2005). Th e need for FXa measurements during prophylactic treatment of 
LMWH has not been defi ned. Th ere is no evidence to show that a certain 
FXa level during pregnancy prevents VTE and many experts recommend 
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a fi xed dose of LMWH throughout pregnancy (Greer and Hunt 2005). 
However, some authors recommend higher prophylactic doses of LMWH 
in morbidly obese patients (Scholten et al 2002). Whether or not peak or 
nadir values of FXa should be measured is also unclear.
Th e effi  cacy of treatment can be evaluated by assessing post-thrombotic 
symptoms and the patency of thrombotic veins. Our study showed no 
diff erences in the occurrence of post-thrombotic symptoms aft er either 
of the heparin treatments during pregnancy. Diagnostic delay (time from 
symptoms to beginning of treatment) refl ects diffi  culties in diagnosing 
DVT during pregnancy (Garcia-Rio et al 1996). However, a delay of one 
week (mean in both groups) before diagnosis seemed not play a role in the 
frequency or severity of post-thrombotic syndromes. In 55% of the patients, 
compression ultrasonography was repeated. Th e re-canalization rate of the 
thrombotic vein tended to be higher in the LMWH group than in the UFH 
group, but as this evaluation was off ered only to patients with symptoms, 
we cannot give any defi nitive answer as to whether or not LMWH is better 
in this sense. 
Th e prevalence of PTS aft er DVT is unknown, the frequency ranging 
between 20% and 100% (McColl et al 1999) depending on predisposing 
factors and wide variability of criteria of PTS. Th ere are diff erent clinical 
scales to diagnose PTS. Recently, Kahn et al (2006) reported that the Villalta 
scale may overestimate mild PTS, whereas the Ginsberg method (Ginsberg 
et al 2000) could be better as regards the most severe cases of PTS. In our 
study, symptomatic patients were also examined by means of duplex Doppler 
US, and thus the diagnosis of severe PTS could be confi rmed.
Severe PTS (PTS score ≥ 15 or deep venous insuffi  ciency) was observed 
only in three patients of 27 (11%), whereas the total incidence of mild or 
moderate post-thrombotic symptoms was 51% in our study (Ulander et al 
2003). Our results do not support the opinion that pregnant patients with 
DVT are at an elevated risk of developing severe PTS. Similar results have 
been reported previously (Rosfors et al 2001). In their 16-year follow-up 
study showed that proximal DVT is a risk factor as regards the development 
of PTS. On the other hand, there is also evidence that localization of DVT 
(distal or proximal) is a relatively poor prognostic factor of PTS (Janssen 
et al 1997). However, the prognosis is poorest when thrombosis has largely 
aff ected the deep venous vasculature, causing valvular incompetence. Only 
10–30% of patients are symptom-free aft er iliac DVT (AbuRahma et al 
2001, Janssen et al 1997). Since DVT during pregnancy is oft en massive and 
proximal (in our study 59%), it has been concluded that these patients are at 
an extremely high risk of developing PTS. In addition, the prolonged venous 
stasis caused by the gravid uterus, and lack of physical exercise at the end 
of pregnancy may worsen the outcome of DVT. Recurrent DVT has been 
reported to enhance the risk of PTS 6-fold compared with patients without 
recurrence (Prandoni et al 1996), and the risk of recurrent DVT is highest 
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during the fi rst year aft er the fi rst episode of DVT (Holmström et al 1999). 
One explanation for the low incidence of severe PTS is that our patients 
were otherwise healthy young women without malignancies associated 
with high risks of recurrent DVT and PTS (Holmström et al 1999). Another 
explanation could be eff ective initial phase treatment of thrombosis, which 
has also been mentioned as a good prognostic factor in the prevention 
of PTS (Ziegler et al 2001). Uterine compression at the end of pregnancy 
predisposes women to DVT. During the early postpartum period the risk 
of recurrence in these healthy active women decreases as a result of uterine 
decompression, but increases as a result of activation of coagulation. In our 
study 25% of the patients with DVT had a history of DVT, thus prophylaxis 
during pregnancy cannot be emphasized enough. In multivariate analysis 
no signifi cant risk factor of PTS was found.
Our studies have certain weaknesses such as small sample size and non-
blinded design. At the time of the study most non-pregnant DVT patients 
were treated with LMWH, which had been proven to be safer than UFH in 
prophylactic use (Pettilä et al 2002). To perform a randomized prospective 
study aimed at investigation of pregnancy outcome and/or maternal 
long-term outcome would have been unrealistic. However, according to 
our results, LMWH seems to be as good as UFH in the acute phase of 
treatment of DVT in terms of safety and effi  cacy. Th ere is also evidence for 
eff ectiveness in the treatment of pulmonary embolism (Kaaja and Ulander 
2002). Th ere were no bleeding complications or cases of heparin-induced 
thrombocytopenia during the treatment period in either of the heparin 
groups. Increasing evidence concerning maternal side eff ects has shown 
the superiority of LMWH over UFH, giving LMWH certain advantages, 
for example in long-term use (Greer and Nelson-Piercy 2005, Warkentin 
and Greinacher 2004). In Finland this was the fi rst randomized study on 
LMWH and UFH, although with a small number of patients, and it can 
be called a landmark study, as aft er it the era of UFH started to decline. 
Our results are similar to those in other, larger, review articles (Greer and 
Nelson-Piercy 2005, Sanson et al 1999). Th e safety profi le, administration 
and costs of treatment with LMWHs are superior compared with UFH, thus 
LMWH has replaced UFH for treatment and prophylaxis of DVT during 
pregnancy. However, further prospective randomized studies are needed 
to establish the defi nitive dose and duration of LMWH in the treatment of 
DVT during pregnancy.
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12.2 The role of thrombophilias in cervical insuffi ciency
Our preliminary data suggest that hereditary thrombophilia might be an 
additional risk factor as regards cervical insuffi  ciency and even premature 
delivery. Cervical insuffi  ciency has similarities with characteristics of 
premature delivery, although it has oft en been handled as a separate medical 
condition. Diff erences between these conditions may be artifi cial and thus we 
can hypothesize that cervical insuffi  ciency is an extreme mode of premature 
delivery.
Interactions between infection, infl ammation and thrombosis are 
well known. Infl ammatory mechanisms upregulate procoagulant factors, 
downregulate natural anticoagulants and inhibit fi brinolytic activity. 
Moreover, infl ammatory mediators appear to increase platelet reactivity 
and production of TF (Esmon 2003). Th e role of thrombin is pivotal in the 
coagulation system but it is important in augmentation of the infl ammatory 
response as well. Th ere is also evidence that thrombin itself has an uterotonic 
eff ect (Elovitz et al 2000, O’Sullivan et al 2004). Premature delivery and 
premature rupture of the membranes are associated with excess generation 
of thrombin (Rosen et al 2001, Chaiworapongsa et al 2002). Th rombin 
enhances the expression of decidual matrix metalloproteinases (MMPs) 
and this is strongly linked to preterm rupture of the membranes (Rosen et 
al 2002, Stephenson et al 2005). Diminished blood fl ow in the spiral arteries 
resulting from activation of coagulation factors may cause hypoxia and lead 
to enhanced eff ects of infl ammatory cytokines. Th us it can be hypothesized 
that in women with thrombophilia, increased thrombin generation could be 
an additive factor as regards the induction of cervical insuffi  ciency.
Our preliminary study showed that thrombophilia may be an additional 
risk factor or premature delivery. However, the role of antithrombotic 
treatment is not clear. Patients at risk of premature delivery are likely 
to be immobilized, which is an independent risk factor of DVT. Th us, 
LMWH treatment should be considered, especially in cases with defi ned 
thrombophilia. Patients with defi ned cervical insuffi  ciency should be tested 
for thrombophilias.
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12.3 The role of new local natural anticoagulants 
(annexins IV and V) in RM 
We showed in our longitudinal study that soluble plasma annexin V levels 
were higher in subjects with aPL antibodies compared with those without 
aPL antibodies. Th e physiological function of annexin V is still not fully 
understood. 
It was recently confi rmed that plasma purifi ed from the blood of 
antiphospholipid-positive subjects can reduce annexin V binding to 
phospholipids (Rand et al 2004). Th e same study group also reported 
decreased annexin V levels in patients with a history of aPL syndrome with 
thrombosis compared with non-aPL thromboembolic patients (Rand et al 
2004). Th e authors hypothesized that in aPL syndrome aPLs not only inhibit 
annexin V binding to phospholipid structures, but also bring about resistance 
to the anticoagulant activity of annexin V. However, there are confl icting data 
concerning plasma levels of annexin V in aPL syndrome. A study conducted 
in non-pregnant patients with systemic lupus erythematosus and secondary 
aPL syndrome showed signifi cantly higher annexin V levels compared 
with controls, but no correlation was found between the presence of aPL 
antibodies and a history of thromboembolic complications (Van Heerde et 
al 2003). We found no statistically signifi cant correlation between annexin 
V levels and pregnancy outcome, although there was a tendency towards 
lower plasma annexin V concentrations in early pregnancy in subjects whose 
pregnancies were successful compared with those whose pregnancies again 
ended in miscarriage. Rand et al (2006), in their retrospective case-control 
study, showed reduced plasma annexin V levels in women with a history of 
RM. Th eir study was performed when the women were in a non-pregnant 
state, thus not correctly refl ecting the situation in early pregnancy. Recently 
published data showed that annexin V levels were higher in amniotic fl uid 
in pregnant women suff ering from IUGR at 18–24 weeks of gestation and 
the authors speculated that there may be some kind of displacing process of 
annexin V from the placenta to amniotic fl uid (Van Eerden et al 2006).
Although annexins IV and V have similar anticoagulant properties, 
their particular eff ects during pregnancy seem to be diff erent. Masuda 
et al (2004) showed that plasma levels of annexin IV in pregnancy were 
unchanged compared with the non-pregnant state and they remain 
unchanged throughout pregnancy. Interestingly, plasma levels of annexin IV 
increased rapidly in the maternal circulation aft er delivery. Th is phenomenon 
has been suggested to refl ect an anticoagulant role of annexin IV in the 
prevention of DIC (Masuda et al 2004). In our study, annexin IV levels 
in early pregnancy did not diff er as regards the presence or absence of 
antiphospholipid antibodies, or the outcome of pregnancy. Our results are 
similar to those presented in the currently published literature.
Final connections between plasma annexin V levels, anticoagulant activity 
and thromboembolic complications cannot be made. However, we can 
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speculate that a local source of annexin V on placental anionic phospholipid 
surfaces is probably important for maintenance of pregnancy and placental 
development, and its role in the systemic circulation remains unclear. It 
should be pointed out that in the present study it is possible that the number 
of subjects was not large enough to achieve statistically signifi cant results as 
regards pregnancy outcome. 
12.4 Polymorphism of TM and EPCR genes
It has been shown that many cases of RM and other pregnancy complications 
are caused by defects in maternal hemostatic responses, leading to 
disturbances of the uteroplacental vasculature and, in some cases, subsequent 
fetal loss. While mutations in TM or EPCR genes may cause thrombophilia 
in the mother, and thereby constitute a risk factor for spontaneous 
abortions, homozygous mutations in the fetus may cause miscarriage via 
other mechanisms (Isermann et al 2001). In mice an important role for the 
TM-protein C-EPCR system in placental development and maintenance 
of pregnancy is fi rmly established (Healy et al 1995, Gu et al 2002), but 
the relevance of these mechanisms as regards pregnancy-associated 
complications in humans remains unknown. Th e data on mouse models, 
the known sequence homology of murine and human TM and EPCR genes, 
and the similar type of placentation in both species (Dittman and Majerus 
1989, Cross et al 1994), however, suggest that TM and EPCR genes are 
candidates as regards RM.
We studied two thrombophilia-related genes, those for TM and EPCR, 
for possible mutations in patients with RM. Excluding the common variants, 
the mutation rate in TM and EPCR genes was low. Our results suggest that 
clear-cut mutations in the TM or EPCR genes are not a major cause of RM 
in Finnish women. However, some mutations and variants may play a role, 
as indicated by the mouse models. In this study we detected two interesting 
variations, c.323-9_336dup in the EPCR gene and 1728+23_+40del in the 
TM gene, which may have a role in spontaneous abortions. Th e c.323-
9_336dup variation is a truncating mutation in exon 3 of the EPCR gene, 
previously identifi ed in a patient with pregnancy loss. Th e 1728+23_+40del 
mutation is a newly identifi ed variation in the 3’UTR region of the TM gene. 
As these mutations were rare in our series, more patients/couples should be 
studied to determine their exact role in RM. 
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13. Conclusions
I. Low molecular weight heparin is as good as unfractionated heparin in the 
acute phase treatment of deep venous thrombosis during pregnancy. Th e 
safety profi le and ease of administration of LMWHs are superior compared 
with UFH and thus use of LMWH is recommend during pregnancy. 
II. Th e prevalence of severe post-thrombotic syndrome (PTS) aft er deep 
venous thrombosis was low, although DVT during pregnancy is oft en 
massive and proximal. Th ere were no correlations between treatments and 
prevalence of PTS. Low molecular weight heparin seems to be eff ective and 
safe in the long term. 
III. Hereditary thrombophilia can be an additional risk factor as regards 
cervical insuffi  ciency and even premature delivery. Th is could open new 
treatment modalities (LMWH).
IV. Soluble plasma annexin V levels correlated with the presence of aPLs 
at the beginning of pregnancy in women with a history of RM. Annexin V, 
as an anticoagulant protein of phospholipid surfaces, can be displaced by 
aPLs, leading to enhancement of coagulation. However, possibly because of 
a small number of patients, we were unable to show if this association could 
be related to pregnancy outcome.
V. Our results suggest that mutations in the TM or EPCR genes are not a 
major cause of RM in Finnish women.
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Appendix I: Hemostatic mechanism during pregnancy
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Appendix II. Clinical scale of Post Th rombotic Syndrome (PTS) (Villalta et al 1994)











Total score ≥ 15 means severe PTS, 5–14 means mild or moderate PTS
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Appendix III. Classifi cation of lower extremity venous disease (CEAP) (Porter and 
Moneta 1995)
C. Clinical fi ndings (0–6), A=asymptomatic S=symptomatic
class 0: No sign of venous disease
1 Teleangiectases, livero reticularis
2  Varicose veins
3 Edema without skin changes
4 Varicose disease-associated skin changes such as 
 hyperpigmentation, eczema
5 Skin induration as above and old healed ulceration
6 Skin induration as above and active ulcer
E. Etiological classifi cation, C=congenital, P=primary, unknown etiology, 
S=secondary/acquired
EC / EP / ES
A. Anatomy, Superfi cial / deep / perforator 
Superfi cial veins A S1–5
1 Teleangiectases 
  Vena saphena magna
2   above knee
3   below knee
4  Vena saphena parva
5 Superfi cial, no association with main veins
Deep veins A D6–16
6 Vena cava inferior
  Vena iliaca
7  communis
8  interna
9   externa 




13   superfi cialis
14 Vena poplitea
15  Vena tibiales (ant/post/peron)
16 Muscle veins (gastrocnemius, soleus)
Perforator A P17, 18 
17 Femoral
18 Crural
P. Pathophysiology, PR=refl ux, PO=obstruction, PR/O=refl ux and obstruction
